Novartis Institutes for BioMedical Research
SAF312
Clinical Trial Protocol CSAF312X2201
A randomized, v ehicle -controlled, subject and inv estigator -
masked, proof -of-concept study  to evaluate the use of 
topical ocular SA F312 in the treatment of postoperativ e 
ocular pain in patients undergoing photorefractiv e 
keratectomy  (PRK) surger y
Document type: Amended Protocol Version
EUDRACT number: N/A
Version number: v02(Clean )
Clinical Trial Phase: Phase II
Release date: 11-Apr-2017
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Novartis Confidential Page 2
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  conduct. Note: The SOM will not be part of the Clinical Study  Report.
Notification of serious adverse events
Dear Investigator,
You must report a serious adverse event (SAE) (initial or follow -up) to Novartis as 
summarized below.  Refer to Section 9.2of the protocol for SAE criteria and additional 
requirements.  See also page 2 of the Site Operations Manual for further details on the method 
of reporti ng a SAE.
Complete SAE report
Submit SAE report to Novartis Drug Safet y and Epidemiology  (DS&E) within 24 hours 
after awareness of the SAE
Notify  the Novartis Medical Lead
The fax number(s) and email address(es) are located in the Site Operations Manual.
Novartis Confidential Page 3
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Table of contents
Notification of serious adverse events ................................................................................. 2
Table of contents ................................................................................................................. 3
List of tables ........................................................................................................................ 6
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Pharmacokinetic definitions and sy mbols ........................................................................... 9
Glossary  of terms ............................................................................................................... 10
Protocol sy nopsis ............................................................................................................... 18
1Introduction ....................................................................................................................... 21
1.1 Background ............................................................................................................ 21
1.2 Nonclinical data ..................................................................................................... 21
1.2.1 Teratogenicity  and reproductive toxicity  data ....................................... 23
1.3 Clinical data ........................................................................................................... 23
1.3.1 Human safet y and tolerability  data ....................................................... 23
1.3.2 Human pharmacokinetic data................................................................ 25
1.3.3 Human pharmacod ynamic data ............................................................. 25
1.4 Study  purpose ........................................................................................................ 26
2Study  objectives and endpoints ......................................................................................... 26
2.1 Primary  objective(s) ............................................................................................... 26
2.2 Secondary  objective(s) ........................................................................................... 26
3Investigational plan ........................................................................................................... 27
3.1 Study  design ........................................................................................................... 27
3.2 Rationale of study  design ....................................................................................... 29
3.3 Rationale for dose/regimen, route of administration and duration of treatment.... 30
3.4 Rationale for choice of c omparator ....................................................................... 32
3.5 Rationale for choice of background therap y.......................................................... 32
3.7 Risks and benefits .................................................................................................. 32
3.7.1 Blood sample volumes .......................................................................... 34
4Population .......................................................................................................................... 35
4.1 Inclusion criteria .................................................................................................... 35
4.2 Exclusion criteria ................................................................................................... 35
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 4
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
5Restrictions for Study  Subjects ................................ ................................ ......................... 37
5.1 Contraception requirements ................................ ................................ ................... 37
5.2 Prohibited treatment ................................ ................................ ............................... 38
5.3 Dietary  restrictions and smoking ................................ ................................ ........... 38
5.4 Other restrictions ................................ ................................ ................................ ...38
6Treatment ................................ ................................ ................................ ........................... 39
6.1 Study  treatment ................................ ................................ ................................ ......39
6.1.1 Investigational treatment and control drugs ................................ .......... 39
6.1.2 Additional study  treatment ................................ ................................ ....39
6.2 Treatment arms ................................ ................................ ................................ ......40
6.3 Treatment assignment and randomization ................................ ............................. 40
6.4 Treatment blinding ................................ ................................ ................................ .40
6.5 Treating the subject ................................ ................................ ................................ 41
6.6 Permitted dose adjustments and interruptions of study  treatment ......................... 41
6.7 Emergency  breaking of assigned treatment code ................................ .................. 42
6.8 Treatment e xposure and compliance ................................ ................................ .....42
6.9 Recommended treatment of adverse events ................................ .......................... 43
6.10 Rescue medication ................................ ................................ ................................ .43
6.11 Concomitant treatment ................................ ................................ ........................... 43
7Study  completion and discontinuation ................................ ................................ .............. 44
7.1 Study  completion and post -study  treatment ................................ .......................... 44
7.2 Discontinuation of study  treatment ................................ ................................ ........ 44
7.3 Withdrawal of informed consent ................................ ................................ ........... 45
7.4 Lost to follow -up................................ ................................ ................................ ...46
7.5 Study  Stopping rules ................................ ................................ .............................. 46
7.6 Early study termination by the sponsor ................................ ................................ .46
8Procedures and assessments ................................ ................................ .............................. 47
8.1 Assessment schedule ................................ ................................ ............................. 47
8.2 Informed consent procedures ................................ ................................ ................. 53
8.3 Subject screening ................................ ................................ ................................ ...53
8.4 Subject demographics/other baseline characteristics ................................ ............. 53
8.4.1 Drug screen ................................ ................................ ........................... 54
8.5 Efficacy  / Pharmacod ynamics ................................ ................................ ............... 54
8.5.1 VAS (Visual Analog Scale) pain assessment ................................ ........ 54
8.5.2 Oral analgesics use ................................ ................................ ................ 54
8.5.3 Patient diary ................................ ................................ .......................... 54
Novartis Confidential Page 5
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
8.6 Safet y ..................................................................................................................... 54
8.6.1 Body temperature .................................................................................. 54
8.6.2 Blood Pressure and Pulse Rate .............................................................. 54
8.6.3 Blink Rate .............................................................................................. 54
8.6.4 Visual acuit y.......................................................................................... 54
8.6.5 Slit lamp biomicroscopy ....................................................................... 55
8.6.6 Intraocular Pressure (IOP)..................................................................... 55
8.6.7 Dilated fundus exam ............................................................................. 55
8.6.8 Ocular h yperemia .................................................................................. 55
8.7 Pharmacokinetics ................................................................................................... 55
8.8 Other assessments .................................................................................................. 56
8.8.1 Ocular assessments ................................................................................ 56
8.8.2 Corneal Staining.................................................................................... 56
9Safet y monitoring .............................................................................................................. 57
9.1 Adverse events ....................................................................................................... 57
9.2 Serious adverse event reporting ............................................................................. 59
9.2.1 Definition of SAE ................................................................................. 59
9.2.2 SAE reporting ........................................................................................ 60
9.3 Reporting Medication errors including misuse/abuse ........................................... 60
9.4 Pregnancy  reporting ............................................................................................... 61
9.5 Early phase safet y monitoring ............................................................................... 62
10Data review and database management ............................................................................. 62
10.1 Site monitoring ...................................................................................................... 62
10.2 Data collection....................................................................................................... 63
10.3 Database management and quality  control ............................................................ 63
10.4 Data Monitoring Committee .................................................................................. 64
10.5 Adjudication Committee ........................................................................................ 64
11Data analy sis...................................................................................................................... 64
11.1 Analy sis sets .......................................................................................................... 64
11.2 Subject demographics and other baseline characteristics...................................... 64
11.3 Treatments ............................................................................................................. 64
Corporate Confidential Information
Novartis Confidential Page 6
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
11.4 Analy sis of the primary  variable(s) ....................................................................... 65
11.4.1 Variable(s) ............................................................................................. 65
11.4.2 Statistical model, hy pothesis, and method of analysis .......................... 65
11.4.3 Handling of missing values /censoring/discontinuations ....................... 65
11.4.4 Sensitivity  anal yses............................................................................... 66
11.5 Analysis of secondary  variable(s) .......................................................................... 66
11.5.1 Efficacy  / Pharmacod ynamics ............................................................... 66
11.5.2 Safet y..................................................................................................... 66
11.5.3 Pharmacokinetics .................................................................................. 67
11.5.4 Pharmacokinetic / pharmacod ynamic interactions ................................ 67
11.5.5 Other assessments ................................................................................. 67
11.7 Sample size calculation.......................................................................................... 68
11.8 Power for anal ysis of key secondary  variables ...................................................... 69
12 Ethical considerations........................................................................................................ 70
12.1 Regulatory and ethical compliance ........................................................................ 70
12.2 Responsibilities o f the investigator and IRB/IEC .................................................. 70
12.3 Publication of study  protocol and results ............................................................... 70
13Protocol adherence ............................................................................................................ 70
13.1 Protocol Amendments ........................................................................................... 71
14References ......................................................................................................................... 72
List of tables
Table 6 -1 Overview of study  medication .............................................................. 39
Table 6 -2 Definition of treatment sequences ......................................................... 40
Table 6 -3 Blinding levels ...................................................................................... 41
Table 8 -1 Details for highl y repetitive assessments .............................................. 52
Table 9 -1 Summary  of reporting requir ements for medication errors ................... 61
List of figures
Figure 3 -1 Study  schedule ...................................................................................... 29
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 7
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
List of abbreviations
AE adverse event
AK anterior keratectomy
b.i.d. twice a day
BMI Body Mass Index
CD-ROM compact disc –read onl y memory
CFR Code of Federal Regulation
COAR Clinical Operations, Analy tics & Regions
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CV coefficient of variation
EC Ethics committee
ECG Electrocardiogram
EDC Electronic Data Capture
ePRO electronic Patient Reported Outcomes
FDA Food and Drug Administration
GCP Good Clinical Practice
h hour
IB Investigator's Brochure
ICHInternational Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IOP Intraocular pressure 
IRB Institutional Review Board
IRT Interactive Response Technology
LLQ lower limit of quantification
MedDRA Medical dictionary  for regulatory  activities
mg milligram(s)
mL milliliter(s)
OPAS Ocular Pain Assessment Survey
OU Both ey es (study  eye and fellow ey e)
PD pharmacod ynamic(s)
Novartis Confidential Page 8
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
PK pharmacokinetic(s)
PRK photorefractive keratectomy
SAE serious adverse event
SAP Statistical analy sis plan
SD standard deviation
SE Study  eye
SOM Site Operations Manual
SUSAR Suspected Unexpected Serious Adverse Reactions
t.i.d. three times a day
VAS Visual analog scale 
WHO World Health Organization
Novartis Confidential Page 9
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Pharmacokinetic definitions and sy mbols
AUC0 -tThe area under the plasma (or serum or blood) concentration -time curve from 
time zero totime 't' where t is a defined time point after administration [mass 
x time / volume]
AUCinfThe area under the plasma (or serum or blood) concentration -time curve from 
time zero to infinity  [mass x time / volume]
AUClastThe area under the plasma (or serum or blood) concentration -time curve from 
time zero to the time of the last quantifiable concentration [mass x time / 
volume]
AUCtauThe area under the plasma (or serum or blood) concentration -time curve from 
time zero to the end of the dosing interval tau [mass x time / volume]
AUCtau,ssThe area under the plasma (or serum or blood) concentration -time curve from 
time zero to the end of the dosing interval tau at steady  state [mass x time / 
volume]
Clast The last observed quantifiable concentration [m ass / volume]
CmaxThe observed maximum plasma (or serum or blood) concentration following 
drug administration [mass / volume]
Cmin The lowest concentration observed during a dosing interval.  Cmin can occur 
at 0 hours (pre-dose) or at the end of a lag-phase or at the end of the dosing 
interval if no lag -phase exists. [mass / volume]
Cmin,ssThe lowest plasma (or serum or blood) concentration observed during a 
dosing interval at stead y state [mass / volume]
Racc The accumulation ratio
T1/2 The terminal elimination half -life [time]
Tlast The time point that corresponds to the last measurable concentration [time]
Tmax The time to reach the maximum concentration after drug administration [time]
Novartis Confidential Page 10
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Glossary  of terms
Assessment A procedure used to generate data required b y the study
Cohort A specific group of subjects fulfilling certain criteria
Control drugAny drug (an active drug or an inactive drug, such as a placebo) 
which is used as a comparator to the investigational drug being tested 
in the trial
DosageDose of the study  treatment given to the subject in a time unit (e.g. 
100 mg once a day , 75 mg twice a day )
EnrollmentPoint/time of subject entry  into the study  at which informed consent 
must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)
EpochInterval of time in the planned conduct of a study . An epoch is 
associated with a purpose (e.g. screening, randomization, treatment, 
follow -up), which applies across all arms of a study .
Health y volunteerA person with no known significant health problems who volunteers 
to be a study  participant 
Investigational drugThe study  drug whose properties are being tested in the study ; this 
definition is consistent with US CFR 21 Section 312.3 and Directive 
2001/ 20/EC and is synony mous with “investigational new drug” or 
“test substance”
Investigational 
treatmentAll investigational drug(s) whose properties are being tested in the 
study  as well as their associated treatment controls. This includes any  
placebos, any active controls, as well as approved drugs used outside 
of their indication/approved dosage or tested in a fixed combination. 
Investigational treatment generall y does not include other treatments 
administered as concomitant background therapy  required orallowed 
by the protocol when used within approved indication/dosage.
Medication numberA unique identifier on the label of each study  drug package in studies 
that dispense study  drug using an IRT s ystem.
Non-investigational 
medicinal Product 
(NIMP)Prod ucts which are not the object of investigation (e.g. any 
background therapy  administered to each of the clinical trial subjects, 
regardless of randomization group, rescue medication, active drug 
run-ins etc.)
PartA single component of a study  which conta ins different objectives or 
populations within that single study . Common parts within a study  
are: a single dose part and a multiple dose part, or a part in patients 
with established disease and in those with newl y-diagnosed disease.
Patient An individual with the condition of interest
Novartis Confidential Page 11
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
PeriodA minor subdivision of the study  timeline; divides phases into 
smaller functional segments such as screening, baseline, titration, 
washout, etc.
Premature subject 
withdrawalPoint/time when the subject exits from the study  prior to the planned 
completion of all study  drug administration and assessments; at this 
time all study  drug administration is discontinued and no further 
assessments are planned.
Randomization 
numberA unique identifier assigned to each random ized subject, 
corresponding to a specific treatment arm assignment
Screen Failure A subject who is screened but is not treated or randomized
StageA major subdivision of the study  timeline; begins and ends with 
major study  milestones such as enrollment, randomization, 
completion of treatment, etc.
Study  completionPoint/time at which the subject came in for a final evaluation visit or 
when study  drug was discontinued whichever is later.
Study  drug 
discontinuationPoint/time when subject permanentl y stops taking study  drug for any 
reason; may or may not also be the point/time of premature subject 
withdrawal.
Study  drug/treatmentAny drug (or combination of drugs) administered to the subject as 
part of the required study  procedures; includes investigation al drug, 
active drug run -ins or background therapy .
Study  treatmentAny drug administered to the study  participants as part of the 
required study  procedures; includes investigational drug (s), 
control(s) or non -investigational medicinal product(s)
Study  treatment 
discontinuationWhen the subject permanently  stops taking study  treatment prior to 
the defined stud y treatment completion date
Subject A trial participant (can be a healthy  volunteer or a patient)
Subject numberA unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the 
subject and should be used to identify  the subject throughout the 
study  for all data collected, sample labels, etc.
Treatment numberA unique identifier a ssigned in non -randomized studies to each dosed 
subject, corresponding to a specific treatment arm 
VariableA measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being 
tested in th e study
Novartis Confidential Page 12
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Withdrawal of 
consent (WoC)Withdrawal of consent from the study  is defined as when a subject 
does not want to participate in the study  any longer, anddoes not 
want any further visits or assessments, anddoes not want any further 
study  related contact, anddoes not allow analy sis of already  obtained 
biologic material
Novartis Confidential Page 13
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Corporate Confidential Information
Novartis Confidential Page 14
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Corporate Confidential Information
Novartis Confidential Page 15
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Corporate Confidential Information
Novartis Confidential Page 16
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Corporate Confidential Information
Novartis Confidential Page 17
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Corporate Confidential Information
Novartis Confidential Page 18
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Protocol sy nopsis
Protocol 
numberCSAF312X2201
Title A randomized, vehicle -controlled, subject and investigator -masked, proof -of-
concept study  to evaluate the use of topical ocular SAF312 in the treatment of 
postoperative ocular pain in patients undergoing photorefractive keratectomy 
(PRK) surger y
Brief title Study of SAF312 as an eye drop for treatment of eye pain following 
photorefractive keratectomy (PRK) surger y
Sponsor and 
Clinical Trial 
PhaseNovartis
Phase II
Intervention 
typeDrug
Study type Interventional 
Purpose and 
rationaleThe purpose of this study is to determine if SAF312  eye drops four times 
daily has an adequate safety  and efficacy profile to justify further clinical 
development for the treatment of ocular pain associated with corneal epithelial 
defect such as after PRK surgery
Primary 
Objective(s)To evaluate pain control in the immediate post -operative period.
Secondary 
ObjectivesTo evaluate the efficacy  of SAF312 eye drops for reducing use of oral analgesics 
following PRK procedure.  To assess safety  and tolerability of SAF312 eye drops 
four times daily. 
To evaluate pain severity post -operatively.
To assess the systemic exposure after ocular dosing of SAF312  eye drops 
four times daily at various time points in PRK patients.
Study design This is a proof -of-concept, subject and investigator -masked, randomized, vehicle 
controlled study  of SAF312 administered as eye drops in addition to standard of 
care treatment in patients after photorefractive keratectom y (PRK) surger y. 
Patients will be randomized to two sequences: 1) SAF312, followed by placebo, or 
2) placebo, followed by SAF312. Each patient will receive the assigned dose four 
times daily for 72 hours following PRK surger y on their study  eye (Day 1, 
Periods 1 and 2).  The initial study  eye will be the non-dominant eye as 
established at screening and in agreement of the patient and the PI. Each patient will 
return for follow -up visits on Day s 2, 3, 4 and 8 after surgery of Periods 1 and 2.
Population Approximately 40male and female patients who are eligible for PRK surgery and 
between 18 and 75 years old (inclusive). 
Key Inclusion 
criteriaMale and female patients age 18 to 75 who are eligible for bilateral PRK 
surgery.
Normal eye exam except for refractive error at baseline.
Planned m yopia correction should not exceed -4.00 Diopters (sphere) and 
3.00 diopters of astigmatism , with spherical equivalent not higher than -4.50, 
confirmed by manifest refraction at baseline. Monovision treatment is allowed .

Novartis Confidential Page 19
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Key Exclusion 
criteriaMonocular patient (including amblyopia) or best corrected visual acuity score 
worse than 20/80 (Snellen) ,or 55 letters (EDTRS), at baseline.
Any systemic or ocular disease that might affect wound healing (such as 
severe rheumatoid arthritis or diabetes or history of keloid formation) or a 
history of ocular trauma, uveitis, infection, or inflammation in the 6 months 
prior to baseline.   Patients with mild, well controlled diabetes with no evidence 
of ocular or systemic complications of diabetes can be included.
Patients with active inflammatory  or infectious ocular conditions, severe or 
progressive retinal disease, and use of topical or systemic stero ids, or use of 
coumadin or similar drugs within the last 6 months prior to baseline.
Patients with any corneal dystrophy (epithelial, stromal or endothelial) or any 
cornea disease (including significant scarring, ocular herpes or pterygium).
Previous refra ctive or corneal surger y (such as LASIK, PRK, radial 
keratotomy , pter ygium removal, corneal transplantation).
History of allergic or hypersensitivity reaction or significant adverse events to 
any of the drugs to be used in this study including: 
tetracaine or similar topical ocular anesthetic
NSAIDs and aspirin
oral analgesic (including acetaminophen and codeine)
antibiotics
steroids
inability to tolerate or wear bandage contact lens
Chronic pain of any etiology or any significant illness which has not resolved 
within two (2) weeks prior to initial dosing.
Concurrent therapy or history of chronic therapy or abuse of sy stemic or 
ocular NSAIDs, analgesics, pain medication (including gabapentin or 
pregabalin and similar), opiates or cannabis. Patients with use of any topical 
eye medication except for lubricating eye drops within two weeks prior to 
surgery, in the study eye will be excluded. Patients with any use of topical or 
systemic NSAIDs during the 30 day s befor e the study, or use of Restasis®
within the 3 months prior to surgery will also be excluded.
History of drug abuse or unhealthy alcohol use within the 12 months prior to 
dosing. Unhealthy alcohol use is defined as a history of, or current alcohol 
misuse/abuse, defined as “Five or more drinks on the same occasion on each 
of 5 or more day s in the past 30 days."
Subjects using CPAP or other sleep apnea devices.
Subjects who do not weigh at least 50 kg, or who do not have a body mass 
index (BMI) within the range of 18 -35 kg/m2. BMI = Body weight (kg) / 
[Height (m)]2
Pregnant or nursing (lactating) women .
Study treatmentSAF312 and placebo, multiple topically delivered doses
Efficacy/PD 
assessmentsVisual Analog Scale (VAS) for pain
Incidence of and amount (mg/kg of body weight) of rescue oral analgesics 
needed in each treatment period
Novartis Confidential Page 20
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Key safety 
assessmentsAdverse event monitoring -AEs and SAEs
Vital sign monitoring (blood pressure, pulse rate, and body temperature)
Ocular exam and assessment results
Epithelial defects
Tear production
Blink rate
Size of epithelial defect by slit lamp exam
Ocular hyperemia
Dilated fundus exam
Intraocular pressure (IOP)
Visual acuity
Other 
assessments
Data analysis The primary efficacy  analysis will assess the effect of SAF312 eye drops on the 
pain visual analog scale (VAS) pain assessmen t prior to the 6 hour dose 
post- operatively compared to vehicle, and the average ocular pain VAS 
assessments from the first post-operative asse ssment up to the pre-dose 12 hour 
post- operative assessment compared to vehicle. The secondary efficacy analysis 
will assess the effect of SAF312  eye drops on whether patients need oral 
analgesics in 24 hours, 2 days, and 3 days post-operatively compa red to vehicle, 
as well as the amount of oral analgesics needed in 12 hours, 24 hours, 2 days, 
and 3 days post -operatively compared to vehicle.
Key words SAF312, proof -of-concept, efficacy , ocular pain, photorefractive keratectom y, PRK
Corporate Confidential Information

Novartis Confidential Page 21
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
1 Introduction
1.1 Background
SAF312, a potent inhibitor of the transient receptor potential cation channel subfamily  V 
member 1 (TRPV1), is currentl y in development as topical ocular eye drops for the treatment 
of post -operative pain after photorefractive keratectomy  (PRK).
In the oral administration program, SAF312 was evaluated in a total of four clinical studies 
(SAD, MAD, PoC for post -operative dental pain and PoC for neurogenic detrusor overactivity 
due to spinal cord lesions). The development of oral SAF312 did not progress because of 
dose-dependent inhibition of noxious heat pain perception.
In the Proof of Concept study  of SAF312 for postoperative pain after PRK the dose of 1 drop 
of SAF312  4 times daily  for 3 day s will be used , as this was estimated as the therapeutic 
dose and provides a margin of safet y from the MTD that was at the same drug concentration 
but at 8 times daily  for 7 day s. Pain after PRK is currentl y partially  treated with Non-Steroid -
Anti- Inflammatory  (NSAID) or diluted anesthetic ocular drops; both groups of drugs have the 
side effect of delay ing wound healing.  
 
There is an unmet medical need for pain control using a topical ocular drug that does 
not delay  wound healing.
The most relevant data for the present study are summar ized in the sections below. 
Fordetailed information, please refer to the IB.
1.2 Nonclinical data
SAF312 is a selective, non-competit ive, reversible inhibitor of TRPV1 channels. SAF312 
inhibited capsaicin, low pH and anandamide stimulation of human TRPV1 with I C50values of 
12, 5, and 10 nM, respectively . Characterization of the selectivity  of SAF312 resulted in no 
activity  of >50% inhibition at 10 μM being observed for a total of 278 GPCRs, transporters, 
ion channels, nuclear receptors and enzymes. SAF312 was highl y selective versus other TRP 
channel family  members and had no activity  against estrogen receptors. SAF312 exhibits 
pharmaco dynamic activity  in acute and long lasting inflammatory  hyperalgesia nonclinical 
models. SAF312 showed sustained analgesic properties upon repeated oral dosing. 
Recent evidence has indicated a link between TRPV1 inhibition and hyperthermia, and this 
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 22
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
was confirmed for SAF312 in clinical studies. However, topical dosing in the eye will limit 
systemic effects of SAF312 while achieving inhibition of corneal TRPV1.
Accumulating data indicates a primary  role for TRPV1 in ocular pain. TRPV1 is expressed in 
several corneal cell types in humans including the corneal epithelium, stroma and 
endothelium ( Zhang et al 2007 , Yang et al 2013a , Mergler et al 2010 ) and also has been 
localized to t he ophthalmic branch of trigeminal nerve endings in the mouse cornea 
(Bates et al 2010 ). A role for TRPV1 in neurogenic pain in the cornea may be assumed given 
the co-local ization of TRPV1 with substance P and calcitonin -gene -related peptide (CGRP) 
receptor in rat corneal neurons (Murata a nd Masuko 2006 ) and by the fact that TRPV1 
agonists can trigger release of tach ykinins (reviewed in Yang et al 2013b ).
The role of TRPV1 in wound healing in the eye is complex. TRPV1 knockout mice were 
reported to have reduced corneal epithelial migration and proliferation following epithelial 
debridement (Sumioka et al 2 014). However, homozy gous TRPV1 knockout mice were 
reported to have reduced inflammation and fibrosis in a mouse corneal wound healing model 
(Okada et al 2 011). Additionally , treatment with a TRPV1 agonist topically  on the cornea, 
which ablated TRPV1 -expressing corneal neurons, had an analgesic effect without damaging 
the cornea or impairing corneal wound healing in mice ( Bates e t al 2010 ), suggesting that loss 
of TRPV1 activit y reduces pain sensation and does not affect wound healing. 
Moreover, TRPV1 activation by hypertonic stress in human corneal epithelial cells induced 
the release of inflammatory  cytokines (Pan et al 2 011 ). These studies clearl y show a role for 
TRPV1 in corneal nociception and i nflammatory  responses in the cornea. Expression of 
TRPV1 has been confirmed in the human cornea epithelium and stroma and in corneal nerves.
Overall, there is a well-validated role for TRPV1 in corneal nociception. SAF312 is a potent 
antagonist of TRPV1 that achieves therapeutic levels in the cornea following topical 
administration. Unlike steroids or NSAIDS, topical treatment of SAF312 did not affect the 
rate of corneal wound healing. It is expected that topical ocular dosing of SAF312 will result 
in minimal systemic exposure, below that associated with heat perception and hyperthermia, 
while preferentiall y targeting TRPV1 in the corneal nerve to reduce postoperative pain 
associated with PRK .
Corporate Confidential Information
Novartis Confidential Page 23
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
1.3 Clinical data
1.3.1 Human safety  and tolerability  data
 The most frequent ocular adverse events in the SAF312 treated 
patients were corne al staining, hyperemia and mild anterior chamber inflammation, in levels 
similar to placebo (refer to I nvest igator's Brochure for details).
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 24
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
For oral SAF312,  
 A total of 379 subjects  
have been exposed to study  medication (271 of those to SAF312). 
 
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 25
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Corporate Confidential Information
Novartis Confidential Page 26
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
1.4 Stud y purpose
To determ ine if SAF312  eye drops four times daily has an adequate safet y and efficacy 
profile to justify  further clinical development for the treatment of ocular pain associated with 
corneal epithelial defect such as after PRK surgery.
2 Study  objectives and end points
2.1 Primary  objective(s)
Primary objective(s) Endpoints related to primary objective(s)
To evaluate pain control in the 
immediate post-operative 
period.Visual analog scale (VAS) pre -dose pain assessment 
at 6 hours post -operatively
Average ocular pain VAS assessments from the first 
post-operative assessment up to the pre -dose 12 hour 
assessment
2.2 Secondary  objective(s)
Secondary objective(s) Endpoints related to secondary objective(s)
To evaluate the efficacy  of 
SAF312  eye drops four 
times daily  for reducing use of 
oral analgesics following PRK 
procedure Incidence of and amount of rescue oral analgesics 
needed in 12 hours, 24 hours, 2 day s, and 3 day s 
post-operativel y after each P RK surgery .
To assess safety  and 
tolerability  of SAF312  
eye drops four times dailyAEs and SAEs
Visual acuit y, intraocular pressure (IOP), dilated 
fundus exam, ocular h yperemia
Size of epithelial defect by  slit lamp exam
Blink rate, tear production, 
Vital signs (blood pressure, pulse rate, and bod y 
temperature)
To evaluate pain severity post-
operativel yAll VAS measurements during the first 3 day s after 
surgery
To assess the s ystemic 
exposure after ocular dosing of 
SAF312  eye drops four 
times daily  at various time 
points in PRK patientsPlasma concentration of SAF312

Novartis Confidential Page 27
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
3 Investigational plan
3.1 Stud y design
This is a proof -of-concept, subject and investigator -masked, randomized, vehicle controlled 
study  of SAF312 administered as eye drops in addition to standard of care treatment in 
patients after photorefractive keratectom y (PRK) surgery . PRK surgery  is performed as an 
outpatient procedure under topical anesthesia with removal of the corneal epithelium to 
expose the stroma for the laser ablation, as described in the SOM. SAF312 dosing will be as 
single eye drop of  suspension , administered four times daily (every  six 
hours) in one ey efrom immediate post -op (time 0) to last dose at 72 hours .
Each patient, if eligible, will participate in this 2 treatment period, cross over study. 
Patients will undergo PRK surgery  on 2 separate occasions (periods), one eye at a time. 
Patients will be randomized to receive SAF312 or vehicle following procedure 1 and the 
alternate following procedure 2 (Figure 3-1).  Patients and investigator site staff will remain 
maske d to treatment.  Sponsor staff will be unmasked for evaluation of adverse events and for 
interim anal ysis, as detailed in Section 6.4 . 
SAF312 has been shown to be safe in humans with intact corneas (CSAF312X 2101 study ). 
Corporate Confidential Information
C
o
r
p
o
r
a
t
e 
C
o
n
fi
d
e
n
ti
a
l 
I
n
f
o
r
m
a
ti
o
n
Corporate Confidential Information
Novartis Confidential Page 28
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Approximately  40patients will be randomized to two sequences to achieve about 
30evaluable patients : 1) SAF312, followed by placebo (n= 20, or 2) placebo, followed by 
SAF312 (n=20. Each patient will receive the assigned dose, one drop four times daily  for 72 
hours following PRK surgery on their study  eye (Day 1, Periods 1 and 2).  The initial study 
eye will be the non- dominant eye as established at screening and in agreement of the patient 
and the PI. Each patient will return for follow -up visits on Day s 2, 3, 4 and 8 of Period 1 aft er 
surgery  in the first eye, with optional daily  visits to follow the patient until wound healing is 
complete . If there is any  complication or any  reason to not have surgery  in the second ey e, the 
patient will not have the second ey e surgery  performed.
Patients will have PRK surgery  on their second study  eye (dominant eye) on Period 2, Day 1.  
The PRK surgery  of the second eye should be performed after the epithelial defect of the first 
eye is resolved and at the discretion of the PI.  After the second P RK, patients will receive the 
opposing treatment four times daily  for 72hours following the PRK surgery .  Patients will 
return daily for the first 3 postoperative days (Period 2, Days 2 -4) and at 1 week after the 
second surgery  (Period 2, Day 8), with optional daily  visits to follow the patient until wound 
healing is complete . An end of study  (EOS) visit will take place 30 days after the second eye 
surgery  (or after final dose of investigational product if the patient ends treatment early in 
period 1).  Toallow flexibility  for scheduling the day of the second surgery , the day of the 
second PRK procedure (start of Period 2) may be as soon as Day 8 assessments are complete, 
or as long as six weeks after the first surgery .
All patients will receive standard of care treatment following PRK surgery , including 
application of a bandage contact lens (Air Optix®Night and Day®Aqua or equivalent ) 
following the procedure and before receiving study  drops for pain. A course of topical ocular 
antibiotic (Moxifloxacin orequivalent 1 eye drop four times daily ) will be started after 
application of first dose of study  drops and will be continued for 4 -7 days. Prednisolone 
acetate ophthalmic 1 eye drop four times daily  will be given for 1 week after PRK, followed 
by taper. Preservative -free unit-dose artificial tears may be used as needed.  The first dose of 
study  drops after each PRK procedure will be administered by site staff. Subsequent doses 
will be self-administered. Whenever drops are administered in sequence, at least 5 minutes 
must pass between eye drop administrations. To summarize, patients will undergo PRK 
procedure, bandage lens is placed on the cornea, SAF312 or placebo is given, after 
approximately  5  m inutes antibiotic is given, and after another 5 minutes, pred nisolone is 
administered. Detailed administration and assessment timing will be included in a table in the 
SOM.
Rescue medication will consist of oral analgesic (acetaminophen 300 mg + codeine 30 mg) as 
needed up to a total of 10 tabs/day  or 1-2 tabs ever y 4 hours.
Corporate Confidential Information
Novartis Confidential Page 29
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Figure 3-1 Study  schedule
After at least 10 patients have had PRK surger y and study  treatment for 72 hours in both eyes 
(completing Period 2, Day 4 visit), enrollment may be paused for an interim analysis (IA).  
Please see Section 11.9 for details.
3.2 Rationale of study  design
The rationale for the key  elements of the study  design are as follows:
Bilateral cross -over design with interim analysis : Cross -over design may be helpful in 
decreasing inter -patient variability  because of different pain tolerance in different 
individuals. Capturing data from both ey es, in conjunction with a n interim analysisafter at 
least 10evaluable patients (20 ey es) allows for a n adjustment in the number of patients 
required to enable the decision to complete the study . There are no prior PRK pain studies 
with bilateral design, only with unilateral surgery , since unilate ral PRK was the standard 
of care several decades ago when these studies were performed (in contrast to today 's 
standard of bilateral simultaneous PRK). So, the interim analysis will estimate the inter -
subject and intra -subject variability  to confirm the po wer calculations for the whole stud y, 
and the sample size may  be adjusted accordingl y.
Primary Endpoint (Electronic Patient Reported Outcome (ePRO) Visual Analog 
Scale (VAS) pain scale) : A validated electronic tool was selected to enable collection of 
sequential data.  Previous studies of pain in PRK have shown that the most intense pain is 
experienced within the first 12 hours after surgery with the peak around 4 -6 hours after 
surgery  (Sher et al 1993 ), and these ar e the timepoints selected for primary  endpoint 
analysis. Since we cannot be sure exactl y when pain will be experienced b y our patients in 
this study , and also it is important clinically  to both try  to decrease the maximum pain as 
well as the overall pain t hat the patient experiences during the immediate postoperative 
period, we decided to evaluate both 6 hours and the period up to 12 hours postoperativel y, 
as primary  endpoints.

Novartis Confidential Page 30
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Rescue oral analgesics: It is not ethical to refuse pain control medication to patients 
postoperativel y as part of a clinical trial, and all prior clinical trials of NSAIDs in 
postoperative pain after PRK used rescue oral analgesics, similar to the Standard of care 
after PRK. This can be a potential confounder of the pain VAS evaluati on. We plan to use 
three approaches when analy zing pain VAS scores to account for the influence of pain 
meds (assuming 4 hours of rescue medication effect): (1) an y recorded VAS score within 
4 hours after use of rescue medication will be considered missing ; (2) all the recorded 
VAS scores will be used; and (3) an y recorded VAS scores within 4 hours after rescue 
medication use will be imputed by  the record taken pri or to the rescue medication. 
Wewill use the first approach as the primary  analy sis, and the o ther two for help with 
decision making.
Randomization and Masking (Patient and investigator masked): Minimizes bias of 
investigators or subjects in assessing subjective readouts, such as adverse events or 
perception of pain (primary  endpoint).
Patient popu lation: PRK is a common procedure with approximately 37,000 surgeries 
performed in the US in 2014 (http://www.statista.com/statistics/271478/number -of-lasik -
surgeries -in-the-us/). The patient population is relativel y homogeneous (usually  under 
45years of age), with healthy  corneas and ey es.  The procedure results in a controlled, 
large, epithelial defect of 8mm with a consistent healing time of 3 to 4 day s.  
Resultant pain is moderate to severe (especiall y the first day ), often requiring oral 
narcotics or other pain killers.  Pain after PRK is curre ntly partiall y treated with 
Non-Steroid -Anti- Inflammatory (NSAID) or diluted anesthetic ocular drops; both groups 
of drugs have a side effect of delaying wound healing. There is no animal model for ocular 
pain co ntrol; however SAF312 when tested in an animal model of PRK in rabbits did not 
delay  wound healing.  Further, TRPV1 antagonists in mice and TRPV1 knock out mice 
showed no delay ed corneal epithelial healing after injury  (Okada et al 2011 ; 
Bates et al 2010 ).  There is an unmet medical need for pain control using a topical ocular 
drug that does not delay  wound healing.
3.3 Rationale for dose/regimen, route of administration and durat ion 
of treatment
SAF312 is a potent inhibitor of the transient receptor potential cation channel subfamily  V 
member 1 (TRPV1). Oral SAF312 was effective in dental pain, but the development of oral 
SAF312 did not progress because of dose -dependent inhibitio n of noxious heat pain 
perception. SAF312 was developed as a topical ocular formulation for the treatment of ocular 
pain from corneal epithelial defect such as after PRK surgery . After PRK surgery  the pain is 
the most intense during the first day after surgery and after the 3rd day (72 hours) it is much 
less, and at a level were topical ocular NSAIDs have no beneficial effect compared to placebo 
(Sher e t al 1993 ). So, the duration of treatment with SAF312 after PRK surgery  in the PoC 
study , is planned for 3 day s (72 hours) after surgery .
C
o
r
p
o
r
a
t
e 
C
o
n
f
i
d
e
n
t
i
a
l 
I
n
f
o
r
m
a
t
i
o
n
Corporate Confidential Information
Novartis Confidential Page 31
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
In this PoC study  we plan to use the topical ocular dose of asingle eye drop of  
suspension, administered four times daily  to a single 
eye  
 
 
 
 
 
The proposed total daily  dose of 3.7 mg of SAF312 from topical ocular 4 -times daily 
administration of a single eye drop of  suspension  dose is 13.5 - fold 
lower than the total daily oral dose of 50 mg (from 25 mgtwice daily dose regimen) which is 
the lowest dose at which impaired heat perception was reported in humans.  
Preliminary assessment of exposure data in humans indicates relative bioav ailability  of 
 suspension topical ocular dose compared to 25 mg oral dose, 
therefore, lower systemic exposures are anticipated from the proposed ocular dose than the 
oral dose.
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 32
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
3.4 Rationale for choice of comparator
Vehicle eye drops will be used as a placebo to mask and compare efficacy  and enable better 
determination of the relation of any  observed ocular adverse events to SAF312.
3.5 Rationale for choice of background therapy
Current standard of care treatment after PRK include bandage contact lens, antibiotic, steroid 
anti-inflammatory , preservative -free artificial tears as well as oral and topical pain control 
medication, as per each surgeons preferences (Woreta et al 2 013). In the current study , we 
keep all the parts of the standard of care treatment after PRK, with the exception of replacing 
topical ocular pain control medication with either SAF312 or placebo, but keeping oral pain 
control re scue medication in place to allow pain control and relief for the patient.
3.7 Risks and benefits
There is no benefit expected for subjects participating in this study . IfSAF312 is shown in the 
future to provide superior analgesic effect compared to curr ent standard of care (NSAIDs or 
diluted topical anesthetic), the patient may experience better analgesia postoperativel y during 
the period treated with SAF312 (but not during the vehicle -treated period), but at present there 
is no information available on analgesic effect of SAF312.
The risk to subjects in this trial will be minimized by  adherence to the eligibility  criteria, close 
clinical monitoring, continuous monitoring of masked emerging safet y and tolerability  data 
and stopping rules.
Potential risks associated with SAF312 (please note different risk profile for topical ocular 
versus oral s ystemic administration)
Topical Ocular SAF312  
 
Ocular safety and tolerability was excellent without dose limiting adverse events. 
All dose cohorts in the single and multiple ascending parts of the study ,  
 showed no dose limiting adverse events and the
maximum feasible concentration  is accepted in the maximum tolerated dose  
 All adverse events of suspected causalit y to SAF312 were 
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 33
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
of mild severity , except for moderate severit y eye irritation that lead to disconti nuation of 
treatment in one patient of the  cohort. The most frequent ocular 
adverse events in the SAF312 treated patients were corneal staining, h yperemia and mild 
anterior chamber inflammation, in levels similar to placebo (more details in the 
Investigators Brochure).
Systemic safety and tolerability of ocular SAF312 was excellent without dose limiting 
adverse events, including no evidence of risks identified with oral SAF312 .  
Oral systemic SAF312 compound specific risks based on clinical safet y and tolerability are:
Impaired temperature perception/sensation neurologic risk. The most commonly  
reported AEs in subjects dosed with SAF312 were transient sensation of cold and chills. 
At the highest tested single doses (800 and 1050 mg) some prolonged sensory  neurologic 
chan ges with intact sensory  and motor nerve conduction were observed. However, this 
risk is negligible as the dose used in this study  is much lower. Dose -dependent changes in 
thermal perception (noxious heat) were noted as assessed by  the “hand immersion test”
(water at 49°C) as part of the multiple dose study  and in the dental pain study . 
Altered thermal perception was dose -dependent and a dose of 12.5 mg or 15 mg lacked 
relevant effects on heat pain perception.  Based on the data it is c oncluded that doses of
15mg SAF312 or less allow for outpatient studies. In order to prevent potential injuries 
resulting from altered thermal perception a series of precautionary  measures are 
implemented in all future clinical studies of oral SAF312.
Autonomic dysreflexia in patients with spinal cord injury. One of the two patients 
treated with oral SAF312 for neurogenic detrusor overactivity  due to spinal cord lesions 
developed circulatory  collapse, headache, nausea, vomiting ,and temperature regulation 
disorder as part of au tonomic dy sreflexia. Patients with an impaired autonomous nerve sy stem 
(e.g. as consequence of spinal cord injury ) may  have a higher risk for developing autonomic 
dysreflexia and should not be treated with SAF312 or other TRPV1 receptor inhibitors.
Corporate Confidential Information

Novartis Confidential Page 34
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Hyperth ermia. Transient increases in body  temperature were observed in subjects dosed 
with SAF312 and these were generally  not associated with clinicall y relevant changes in 
blood pressure or pulse. At repeat doses of 25 mg a mild transient elevation in body  
temp erature was observed and at 12.5 mg SAF312 all reported bod y temperatures were 
within the normal range.
QT interval shortening . The clinical studies performed with SAF312 demonstrated 
transient shortening of the QT interval; none of the QT interval changes was sy mptomatic 
or associated with clinically  relevant arrhy thmias (ventri cular or supraventricular). 
Thelowest QTcF value noted during the single oral dose study  was 342 milliseconds (ms) 
and was observed on day 1 at 1 -2 hours post -dosing in one subject in each of the three 
different dosing groups (i.e., 7.5, 125 and 1050 mg). The lowest QTcF values observed in 
the multiple dosing study were between 355 ms and 364 ms, except one subject (Part B) 
who was discontinued from the study  due to a shortened QTcF of 333 ms compared to 
351ms at baseline, with no associated arrh ythmia after a single dose of 125 mg SAF312. 
The minimum QTcF value measured in patients with post -operative pain treated with 
SAF312 was 347 ms (one subject). The clinical relevance of drug -induced short QTcF 
intervals of this magnitude is presentl y unknown. Recentl y, (Antto nen et al 2007 ) reported 
that a short QTcF interval (<340 ms) was not associated with a higher mortality  in a 
population of non -referral middle -aged subjects.
Women of child bearing potential should be informed that taking the investigational drug may 
involve unknown risks to the fetus if pregnancy  were to occur during the study , and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the subject will not reliably  comply , they 
should not be entered in the study .
There may  be unknown risks of SAF312 which may  be serious.
3.7.1 Blood sample volumes
A maximum of approximately  72 mL  of blood is planned to be collected from each subject as 
part of the study . Additional samples for serum pregnancy  test and monitoring of any safet y 
findings would be in addition to this. This is not consider ed to be a risk for this population.
Timings of blood sample collection are outlined in the Assessment s chedule ,Section 8.1 .
A summary  blood log is provided in the Site Operations Manual, together with instructions 
for all sample collection, processing, storage ,and shipment information.
See Section 8.9 regarding the potential use of residual samples. 
Novartis Confidential Page 35
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
4 Population
Male and female patients who are eligible for PRK surgery  and between 18 and 75 years old 
(inclusive). The study  plans to enroll approximately  40patients to achieve about 30 evaluable 
completers. Sample size may  be adjusted based on the interim anal ysis.  
Subject selection is to be established by checking through all eligibility  criteria at screening, 
with confirmation of select eligibility  criteria at baseline. A relevant record (e.g. checklist) of 
the eligibility  criteria must be stored with the source documentation at the study  site. 
Deviation from any entry  criterion excludes a subject from enrollment into the study . 
Additional subjects may be enrolled when subjects discontinue the study  for reasons other 
than safet y. All patients exposed to investigatio nal product will be included in some analy ses 
such as patients who discontinued or who only had surgery  in one eye will be included in 
safet y analysis (details in the anal ysis plan).
4.1 Inclusion criteria
Population eligible for inclusion in this study  must f ulfill allof the following criteria:
1.Male and female patients age 18 to 75 who are eligible for bilateral PRK surgery .
2.Normal ey e exam except for refractive error at baseline.
3.Planned m yopia correction should not exceed -4.00 Diopters (sphere) and 3.00 diopters of 
astigmatism, with spherical equivalent not higher than -4.50, confirmed by  manifest 
refraction at baseline.   Monovision treatment is allowed.
4.Written informed consent must be obtained before any  assessment is performed.
4.2 Exclusion criteria
Popul ation fulfilling any  of the following criteria are noteligible for inclusion in this study :
1.Monocular patient (including ambl yopia) or best corrected visual acuit y score worse than 
20/80 (Snellen) or 55 letters (EDTRS), at baseline.
2.Any systemic or ocular disease that might affect wound healing (such as severe 
rheumatoid arthritis or diabetes or history  of keloid formation) or a history  of ocular 
trauma, uveitis, infection, or inflammation in the 6 months prior to baseline.   
Especiall yfor diabetes: Patien ts with severe diabetes, uncontrolled diabetes, diabetic 
keratopath y, diabetic retinopathy, diabetic macular edema, diabetic nephropathy , diabetic 
foot ulcers or other s ystemic complications of diabetes are excluded . Patients with mild ,
well controlled dia betes with no evidence of ocular or s ystemic complications of diabetes 
can be included.
3.Patients with active inflammatory  or infectious ocular conditions, severe or progressive 
retinal disease, and use of topical or s ystemic steroids, or use of coumadin or similar drugs 
within the last 6 months prior to baseline.
4.Patients with any  corneal dy strophy  (epithelial, stromal or endothelial) or any  cornea 
disease (including significant scarring (at the discretion of the PI), ocular herpes or 
ptery gium).
5.Previous r efractive or corneal surgery  (such as LASI K, PRK, radial keratotomy , 
ptery gium removal, corneal transplantation). 
Novartis Confidential Page 36
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
6.History  of allergic or hy persensitivity  reaction or significant adverse events to any  of the 
drugs to be used in this study  including:
tetrac aine or similar topical ocular anesthetic
NSAIDs and aspirin
oral analgesic (including acetaminophen and codeine)
antibiotics 
steroids
inability  to tolerate or wear bandage contact lens
7.Chronic pain of an y etiology  or any  significant illness which has not resolved within 
two(2) weeks prior to initial dosing.
8.Concurrent therap y or history of chronic therap y or abuse of s ystemic or ocular NSAIDs, 
analgesics, pain medication (including gabapentin or pregabalin and similar), opiates or 
cannabis. 
Patients with use of an y topical eye medication except for lubricating eye drops within 
two weeks prior to surgery, in the stud y eye will be excluded. 
Patients meeting an y of the following will also be excluded:
(a) an y use of topical NSAIDs during 30 da ys before baseline, OR
(b) systematic/chronic use of s ystemic NSAIDS within 30 day s prior to baseline, OR
(c) occasional use of s ystemic NSAIDS within 3 day s prior to baseline, OR 
(d) use of ocular cy closporine (or similar medication) within the 3 months prior to surgery .
9.Use of other investigational drugs at the time of enrollment, or within 5 half -lives of 
enrollment, or within 30 day s of baseline, whichever is longer; or longer if required by  
local regulations.
10.History  of drug abuse or unhealthy  alcoho l use within the 12 months prior to dosing. 
Unhealthy  alcohol use is defined as a history  of, or current alcohol misuse/abuse, defined as 
“Five or more drinks on the same occasion on each of 5 or more day s in the past 30 day s."
11.Subjects using CPAP or other sleep apnea devices.
12.Subjects who do not weigh at least 50 kg, or who do not have a bod y mass index (BMI) 
within the range of 18 -35 kg/m2. BMI = Bod y weight (kg) / [Height (m)]2
13.Pregnant or nursing (lactating) women.
14.Women of child -bearing potential, de fined as all women phy siologically  capable of 
becoming pregnant, unless they  are using basic methods of contraception during dosing of 
investigational drug. Basic contraception methods include:
Total abstinence from heterosexual intercourse (when this is i n line with the preferred 
and usual lifest yle of the subject). Periodic abstinence (e.g. calendar, ovulation, 
symptothermal, post -ovulation methods) and withdrawal are not acceptable methods 
of contraception
Female sterilization (have had surgical bilatera l oophorectom y with or without 
hysterectom y), total h ysterectomy  or tubal ligation at least six weeks before taking 
investigational drug.  In case of oophorectomy  alone, only  when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment
Novartis Confidential Page 37
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject.
Barrier methods of contraception: Condom or Occlusive cap (diaphragm o r 
cervical/vault caps). For UK: with spermicidal foam/gel/film/cream/vaginal 
suppository
Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS)
In case of use of oral contraception women should be stable on the same pill for a 
minimum of 3 months before taking st udy drug.
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterectom y or tubal ligation at least 
six weeks ago. In the case of oophorectomy  alone, only  when the reproductive status of 
the woman has been confirmed by  follow up hormone level assessment is she considered 
not of child bearing potential.
15.Unable to communicate well with the investigator, to understand and comply  with the 
requirements of the study including use of ePRO device at home and adherence to the 
dosing and visit schedule.
No addition al exclusions may  be applied by  the investigator, in order to ensure that the 
study  population will be representative of all eligible patients.
5 Restrictions for Study  Subjects
A corneal and eye examination consistent with eligibility  for PRK surgery  is needed at 
baseline. 
During recruitment, screening/informed consent review, and baseline visit, the subjects must 
be informed and reminded of the restrictions outlined in this section.
5.1 Contraception requirements
Women of child bearing potential must be informed that taking the study  treatment may 
involve unknown risks to the fetus if pregnancy  were to occur during the study , and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the subject will not reliably  comply , they 
should not be entered or continue in the study .
Please refer to exclusion criteria ( Section 4.2 ) for details of contraception require ments for the 
study .
Novartis Confidential Page 38
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
5.2 Prohibited treatment
No ocular medication other than study  drugs (study  drugs include standard of care drugs such 
as antibiotic and steroid, as well as preservative free artificial tears) will be allowed from the 
first dosing until allof the Study  Completion evaluations have been conducted. All drugs, 
including artificial tears are stored and administered at room temperature only 
(refrigerated/cold eye drops are not allowed with the exception of use during PRK surgery 
inside the operat ing room if desired by  surgeon).
Mitomy cin C must not be used as an intraoperative medication for patients on this study .
No pain medication may be used within 24 hours prior to surgery. No pain medication 
other than rescue analgesics may be used from surgery until 4 days post-surgery for 
ocular or periocular pain.   If a patient requires analgesics at the time scheduled for the 
second surgery , the PI and patient must decide whether the patient will discontinue use of pain 
medication 24 hours prior to the scheduled surgery  (if medically  feasible) or postpone the 
surgery until analgesic use is discontinued .
Should a subject have an incidental and limited need for a medication to be taken at any  point 
during the study  (e.g. antibiotic prophy laxis prior to d ental surger y or for pain relief of pain in 
any other part of the body  or fever, limited use of acetaminophen [e.g., up to 2 tablets of 
325mg ,or ibuprofen up to 2 tablets of 200mg etc.]), the sponsor should be advised, as 
administration of any  concomitant medication may require the subject to be withdrawn.  Total 
acetaminophen dose must be less than 3g/day, including rescue analgesics and any incidental 
need for medication unrelated to ocular pain.
5.3 Dietary  restrictions and smoking
No cannabis use for 4 wee ks before screening until after Study  Completion evaluation.
No cigarettes/use of nicotine products and no alcohol use for 24 hours before dosing and 
until after completion of study  treatment (Day  4 in each period).
5.4 Other restrictions
No strenuous ph ysicalexercise , particularl y contact sports or other activities with a risk of 
contact to the ey es (e.g.basketball ) until the later of: complete healing of epithelial defect 
following each surgery , OR at least one week after each surgery .
Novartis Confidential Page 39
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
6 Treatment
6.1 Stud y treatm ent
Details on the requirements for storage and management of study  treatment, and instructions 
to be followed for subject numbering, prescribing/dispensing and taking study  treatment are 
outlined in the Site Operations Manual.
6.1.1 Investigational treatment an d control drugs
Table 6-1 Overview of study  medication
Drug Formulation Appearance Unit dose PackagingProvided 
by
SAF312 Topical 
ocular dropsColorless to off -
white clear liquid OR 
white to off -white 
uniform suspension  
SAF312 
per 37 µL 
drop sizeSingle use 
droppers 
(preservative 
free)Alcon
SAF312 
vehicle/PlaceboTopical 
ocular dropsColorless to off -
white clear liquid OR 
white to off -white 
uniform suspension NASingle use 
droppers 
(preservative 
free)Alcon
6.1.2 Additional study  treatment
Ancillary  treatments will be provided by  participating sites with funding provided by  Sponsor. 
All patients will receive standard of care ancillary  treatment following PRK surgery , 
including:
A course of topical ocular antibiotic (Moxifloxacin or equivalent 1 ey e drop four times 
daily ):start right after PRK surgery , and after application of first dose of study  eye drop 
and continued for 4 -7 day s, per managing phy sician.
Prednisolone acetate ophthalmic: 1 ey e drop four times daily  will be started right after 
PRK surgery  and after instill ation of antibiotic eye drop and will be given for 1 week after 
PRK, followed by  taper per local procedures.
Preservative -free unit -dose artificial tears may  be used as needed. Artificial tears may  not
be chilled for analgesic effect.  
Whenever drops are administered in sequence, at least 5 minutes must pass between eye drop 
administrations.
To summarize, patients will undergo PRK procedure, bandage lens is placed on the cornea, 
SAF312 or placebo is given, after approximately  5 minutes antibiotic is admini stered, and 
after another 5 minutes, prednisolone is administered. Detailed administration and assessment
timing are included in Table 1-1 of the SOM.
Ancillary  medication must be recorded on the Concomitant medications/Significant non- drug 
therapies CRF.
Corporate Confidential Information
Novartis Confidential Page 40
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
6.2 Treatment arms
Subjects will be assigned to one of the following 2 treatment sequences in a ratio of 1:1 
lasting 3 day s per period.
Table 6-2 Definition of treatment sequences
Sequence Period 1 Period 2
1 SAF312 
4 tim es daily (ever y 6 hours) for 72 hours
(inclusive)Vehicle control to SAF312
4 tim es daily (ever y 6 hours) for 72 hours
(inclusive)
2Vehicle control to SAF312 
4 tim es daily (ever y 6 hours) for 72 hours
(inclusive)SAF312 
4 tim es daily (ever y 6 hours) for 72 hours
(inclusive)
6.3 Treatment assignment and randomization
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. 
Arandomization list will be produced by or under the responsibility of the Sponsor 
Biostatistics & Clinical Data Operations (Statistical Programming) Groups using a validated 
system that automates the random assignment of treatment arms to randomization numbers in 
the specified ratio.
Follow the details outlined in the Site Operations Manual regarding the process and timing of 
treatment assignment and randomization of subjects.
6.4 Treatment blinding
This is a subject and investigator -masked study . Subjects and investigators will remain 
masked to study  treatment throughout the study , except where indicated below.
The identity  of the treatments will be concealed by the use of study  drugs that are all identical 
in packaging, labeling, and schedule of administration, and similar in appearance.
Site staff
With the exception of any unmasked site staff identified below, all site staff (including study 
investigator and study  nurse) will be masked to study  treatment throug hout the study .
Unmasking a single subject at site for safet y reasons (necessary  for subject management) will 
occur via an emergency  system in place at the site (see Section 6.7 ).
Sponsor staff
The following unmasked sponsor roles are required for this study :
Unmasked sample anal yst(s) (PK)
The sample analysts will receive a copy of the randomization schedule, to facilitate analysis 
of the samples. The sample analysts will provide the sample data to the study  team under 
masked conditions unless otherwise allowed.

Novartis Confidential Page 41
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
The study  statistician will be able to access the randomization list for interim analyses and is 
allowed to share unmasked information with the rest of the clinical team as appropriate for 
intern al decision purposes, as outlined in Table 6-3. For example, unmasked summaries and 
unmasked individual data can be shared with the team for interim anal yses.
Study  programmers and other personnel involve d in study  data anal ysis (e.g. biomarker expert) 
are allowed to access treatment assignment information for the purpose of conducting interim 
analyses.
The clinical trial team is allowed to share unmasked results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the study  or the project at 
the time of interim anal yses while the study is ongoing.
All unmasked personnel will otherwise keep randomization lists and data or information that 
could unmask other study  team members confidential and secure except as described above.
Following final database lock all roles may  be considered unmasked.
Table 6-3 Blinding levels
RoleTime or Event
Randomization 
list generatedTreatment 
allocation & 
dosingSafety event 
(single subject 
unblinded)Interim 
Analysis
Subjects/Patients B B B B
Site staff B B UI B
Drug Supply and Randomization 
OfficeUI UI UI UI
Statistician/statistical 
programmer/data analystsB B UI UI
All other sponsor staff not 
identified aboveB B UI UI
B Remains blinded
UI Allowed to be unblinded on individual patient level
6.5 Treating the subject
SAF312 will be administered to the subject via the following route of administration: ocular 
drops.  Drops will be administered at the study  site by the study  personnel during the dayof 
surgery . During the daily follow up postoperative visits, if the patient is at the site during the 
expected time for eye drop administration, the study  personnel may administer the eye drops. 
The remainder of drops will be home administered by the patient .  See the Site Operations 
Manual for further details.
Sponsor qualifi ed medical personnel will be readily  available to advise on trial related 
medical questions or problems.
6.6 Permitted dose adjustments and interruptions of study  treatment
Study  treatment dose adjustments and/or interruptions are not permitted.
Novartis Confidential Page 42
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
6.7 Emergency  breaking of assigned treatment code
Emergency  code breaks must only be undertaken when it is required to in order to treat the 
subject safel y. Most often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient totreat a study  subject who presents with an emergency  
condition. Emergency  treatment code breaks are performed using the IRT. When the 
investigator contacts the system to break a treatment code for a subject, he/she must provide 
the requested subject ident ifying information and confirm the necessity  to break the treatment 
code for the subject. The investigator will then receive details of the investigational drug 
treatment for the specified subject and a fax or email confirming this information. The sy stem 
will automatically  inform the study  monitor for the site and the Study  Team that the code has 
been broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT at any time in case of emergency .   The investigator will need to 
provide: 
protocol number
study  drug name (if available)
subject number.
In addition, the investigator must provide oral and written information to inform the subject 
how to contact his/her backup in cases of emergen cy when he/she is unavailable to ensure that 
un-masking can be performed at an y time.
An assessment will be done by the appropriate site personnel and sponsor after an emergency 
unblinding to assess whether or not study  treatment should be discontinued for a given subject.
6.8 Treatment exposure and compliance
PK parameters (measures of treatment exposure) will be determined in all subjects treated 
with SAF312, as detailed in Section 8.7 .
The investigator must prom ote compliance by instructing the subject to take the study 
treatment and rescue medication exactly  as prescribed and by stating that compliance is 
necessary  for the subject’s safety  and the validity  of the study . Subjects will be instructed that 
failing t o comply  with study  procedures, such as repeatedl y missing doses of study  medication 
or repeatedl y entering incorrect rescue medication use inform ation in the electronic 
Patient Reported Outcomes (ePRO) device may be removed from the study  at the discretio n 
of the investigator in coordination with the Sponsor. The subject must also be instructed to 
contact the investigator if he/she is unable for any reason to take the study  treatment as 
prescribed .
Compliance will be assessed by the Investigator and/or study  personnel at each visit using 
rescue medication counts and ePRO information provided by the subject. This information 
should be captured in the source document at each visit. All study  treatment dispensed and 
returned must be recorded in the Drug Accountability  Log. 
Compliance must be reconciled against patient -reported use in the electronic diary at each 
applicable visit.
Novartis Confidential Page 43
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
6.9 Recommended treatment of adverse events
AEs will be treated at the discret ion of the Investigator and in accordance with current 
medical practice.
 
 
The most common drug suspected adverse events in 
this study  were: corneal staining, hyperemia and mild anterior chamber inflammation 
(moredetails in the IB).  
 
Ocular AEs should be treated accordin g to the t ype of the AE.
Subjects should remain in the study  even after receiving treatments for AEs until the 
Investigator feels that subject discharge is warranted.
Medication used to treat AEs must be recorded on the Concomitant medications/Significant 
non-drug therapies eCRF.
6.10 Rescue medication
Rescue medication is provided by the Sponsor, and will consist of oral analgesic 
(acetaminophen 300 mg + codeine 30 mg). Patients will be instructed to take as needed for 
pain relief up to a total of 10 tabs/day  or 1-2 tabs every  4 hours during the treatment period 
(Visits 2-5 and 7-10) .  Patients must be instructed to complete a VAS for pain assessment 
prior to taking rescue medication.
Use of pain medication after the treatment period (after visits 5 and 10) is per PI discretion, 
and must be recorded on the Concomitant medications/Significant non -drug therapies CRF.
6.11 Concomitant treatment
All prescription medications, over-the-counter drugs and significant non-drug therapies 
(including physical therapy and blood transfusions) administered or taken within the timeframe 
defined in the entry  criteria prior to the start of the study  and during the study , must be recorded on 
the Concomitant medications/ Significant non -drug therapies section of the CRF.
Both temporary  and permanent punctal plugs are allowed at the discretion of the PI, but must 
be recorded on the Concomitant Medication or Medical History  form, respectivel y.
Benzodiazepines and similar medication are allowed in moderation and if absolutel y 
necessary  for a specific patient on a case by  case basis, on day  of surgery  only .
Medication entries should be specific to trade name, the single dose and unit, the frequenc y 
and route of administration, the start and discontinuation date and the reason for therapy .
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 44
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
7 Study completion and discontinuation
7.1 Stud y completion and post -stud y treatment
Each subject will be required to complete the study  in its entirety  and thereafter no further 
study  treatment will be made available to them.
Study  completion is defined as when the last subject completes their Study  Completion visit, 
and any repeat assessments associated with this visit have been documented and followed -up 
appropriatel y by the Investigator, or in the event of an early study  termination decision, the 
date of that de cision.
The final study  visit is conducted at least 30 days after final treatment (study  medication) and 
will serve as safet y follow -up.  Any subjects who discontinue the study  after receivin g 
treatment or are otherwise not seen at the final visit should, at a minimum, have a safet y 
follow -up call conducted at least 30 days after the last study  treatment. The information 
collected is kept as source documentation.  All SAEs reported during this time period must be 
reported as described in Section 9.2and the SiteOperations Manual.  Documentation of 
attempts to contact the subject should be recorded in the source documentation.
7.2 Discontinuation of study  treatment
Subjects may  voluntaril y dis continue study  treatment for an y reason at an y time.
The investigator must discontinue study  treatment for a given subject if, on balance, he/she 
believes that continuation would be detrimental to the subject’s well -being.
Study  treatment must be discontin ued under the following circumstances:
Subject withdraws consent
Pregnancy
Any adverse event graded severe or higher (see severity  grading in Section 9.1 )related to 
study  drug
Emergence of the following adverse events: 
Severe or persistent moderate ocular discomfort as reported b y the subject that is 
outside the expected discomfort from PRK surgery
Cornea or ocular surface epithelial defects (extensive and non -healing) that are 
outside the expected extent and r ate of healing after PRK surgery
Any condition requiring additional or new intraocular surgery  (concurrent or after the 
PRK surgery ) in the study  eye
Any severe intraoperative complication occurred during the PRK surgery . In this case 
the patient will be w ithdrawn from the study  and will not be dosed with any  dose of 
the investigational drug.
Any protocol deviation that results in a significant risk to the subject’s safety
Novartis Confidential Page 45
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Discontinuation of Study/investigational treatment will be at the discretion of the I nvestigator, 
under the following circumstances:
Emergence of the following adverse events: 
Any need for ey e surgery (outside the planned bilateral PRK)
A serious adverse event that, in the opinion of the investigator, is not related to the 
study  drug
Temperature increase to > 39.0oC measured orall y which is sustained for >15 minutes 
at an y time
Hyperthermia (> 38.0oC)-related changes in vital signs which are judged as clinically  
significant b y the investigator (an increase in heart rate to > 120 BPM an d/or a drop in 
blood pressure to <80/40 mmHg)
≥ Grade 2 h ypertension (≥ 24 hour or sy mptomatic increase in BP by  > 20 mmHg 
(diastolic) or to > 160/100)
≥ Grade 2 intraocular inflammation
Corneal edema/corneal opacity  ≥ Grade 1
The appropriate personnel from the site and the sponsor will assess whether study  and 
investigational treatment should be discontinued for any subject whose treatment code has 
been broken inadvertently for an y reason.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they withdraw 
their consent (see protocol Section 7.3). Where possible, they should return for the 
assessments indicated at EOS visit in the Assessment schedule . If they fail to return for these 
assessments for unknown reasons, every  effort (e.g. telephone, e -mail, and/or letter) should be 
made to contact the m as specified in protocol Section 7.4 .
7.3 Withdrawal of informed consent
Subjects may voluntaril y withdraw consent to participate in the study  for any reason at any 
time.
Withdrawal of consent from the study  is defined as when a subject:
Does not want to participate in the study  anymore and
Does not want an y further visits or assessments and
Does not want an y further study  related contacts and
Does not allow anal ysis of already  obtained biologic material.
In thissituation, the investigator must make every  effort (e.g. telephone, e-mail, letter) to 
determine the primary  reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
Novartis Confidential Page 46
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
7.4 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g. dates of 
telephone calls, registered letters, etc. A subject cannot be formally  considered lost to follow -
up until his/her scheduled end of study  visit would have occurred.
7.5 Stud y Stopping rules
Under any of the following conditions, the current study /part will be placed on temporary 
hold and potentially  halted, pending full review of the clinical data by the investigator and 
Sponsor:
Two or more incidents of a similar serious adverse event that, in the opinion of the 
investigator, are related to the stu dy drug
The principal investigator and the sponsor consider that the number and/or severit y of 
adverse events justify  discontinuation of the study .
Any severe or higher adverse event (see severity  grading in Section 9.1 )related to study  
drug
The Sponsor requests it. 
7.6 Early study  termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. Should this be necessary , subjects 
must be seen as soon as possible and treated as a prematurely  withdrawn subject. 
Theinvestigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the subject’s interests. 
Theinvestigator will be responsible for informing IRBs/IECs of the early  termination of the 
trial.
Novartis Confidential Page 47
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
8 Procedures and assessments
8.1 Assessment schedule
Study Phase ScreeningBaselin
eTreatment 12Treatment 22End of 
Study
or 
Early 
Exit
Visit Numbers1Screen 1 2 3 4 5 Opt* 62Opt* 728 9 10 Opt* 11 Opt* 12
Study Day(s) -29 to -2-1
-14 +01 2 3 4 5-7 89 or 
later
1 2 3 4 5-7 89 or 
later30 days 
post-last 
dose 
(study 
med)
Time (post -initial 
dose of treatment 
cycle)- - 0h 1h24h 48h 72h 74h --
0h 1h24h 48h 72h 74h - -
Informed consent X
Inclusion / 
Exclusion criteriaX X
Medical 
history/current 
medical conditionsX X
Ocular history X X
Demography X
Pregnancy test3X X X
Drug screen X X X
Blood Pressure 
and Pulse RateX X X4X4X4X4 XX4,2X4X4X4 X X
Corporate Confidential 
Information
Novartis Confidential Page 48
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Study Phase ScreeningBaselin
eTreatment 12Treatment 22End of 
Study
or 
Early 
Exit
Visit Numbers1Screen 1 2 3 4 5 Opt* 62Opt* 728 9 10 Opt* 11 Opt* 12
Study Day(s) -29 to -2-1
-14 +01 2 3 4 5-7 89 or 
later
1 2 3 4 5-7 89 or 
later30 days 
post-last 
dose 
(study 
med)
Time (post -initial 
dose of treatment 
cycle)- - 0h 1h24h 48h 72h 74h --
0h 1h24h 48h 72h 74h - -
Body temperature X X X4X4X4X4X X4,2X4X4X4X X
Body weight X X
Body height X
Concomitant 
therapiesAs required X
Adverse events As required X
Serious adverse 
eventsAs required
X5
PK blood 
collection6 See table below
PRK Procedure7SE SE4
X X4X4XX4X4X
VAS (Visual 
Analog Scale) 
pain assessment8X X X 
Patient diary8X X
Corporate Confidential 
Information
Corporate Confidential 
Information
Novartis Confidential Page 49
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Study Phase ScreeningBaselin
eTreatment 12Treatment 22End of 
Study
or 
Early 
Exit
Visit Numbers1Screen 1 2 3 4 5 Opt* 62Opt* 728 9 10 Opt* 11 Opt* 12
Study Day(s) -29 to -2-1
-14 +01 2 3 4 5-7 89 or 
later
1 2 3 4 5-7 89 or 
later30 days 
post-last 
dose 
(study 
med)
Time (post -initial 
dose of treatment 
cycle)- - 0h 1h24h 48h 72h 74h --
0h 1h24h 48h 72h 74h - -
Oral analgesics 
use9 X X X X X X
Blink Rate OU10OU OU4OU4OU4OU4OU OU4,2OU4OU4OU4OU OU 
See table below
Visual acuity OU10OU SE4SE4SE4OU SE4SE4SE4SE OU
Dominant eye test X7,12,10
Ocular hyperemia OU10OU SE4SE4SE4SE4OU SE4,2SE4SE4SE4SE OU
Slit lamp 
biomicroscopyOU10OU SE4SE SE4SE4SE4OU SE4,2SESE4SE4SE4SEOU 
Corneal Staining OU10OU OU13OU13OU
SESE4SE4SE4SE* SE* SE* SESE4SE4SE4SE* SE* SE*
OUSE
14 SE4SE4SE* SE* SE* SE SE4SE4SE* SE* SE*
Tear Production OU10SE SE OU SE SE OU
Corporate Confidential 
Information
Corporate Confidential Information
Novartis Confidential Page 50
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Study Phase ScreeningBaselin
eTreatment 12Treatment 22End of 
Study
or 
Early 
Exit
Visit Numbers1Screen 1 2 3 4 5 Opt* 62Opt* 728 9 10 Opt* 11 Opt* 12
Study Day(s) -29 to -2-1
-14 +01 2 3 4 5-7 89 or 
later
1 2 3 4 5-7 89 or 
later30 days 
post-last 
dose 
(study 
med)
Time (post -initial 
dose of treatment 
cycle)- - 0h 1h24h 48h 72h 74h --
0h 1h24h 48h 72h 74h - -
Intraocular 
Pressure (IOP)OU10OU SE SE OU
Dilated fundus 
examOU10OUOU
SE15SE15,*SE15SE15,*SE15SE15,*SE15SE15,*
Study completion 
informationX
Corporate Confidential Information
Novartis Confidential Page 51
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
1Visit structure given for internal programming purpose only
2Treatment Period 2 may begin any time after wound closure from Period 1 surgery and Day 8 assessments completed (including on Day 8), and up to 6 weeks post first 
surgery.  If Day 1 of Treatment Period 2 is less than 1 week from Day 8 of Treatment Period 1, pre -dose ocular and vital sign assessments (e.g., Blink rate, Body 
temperature) do not need to be repeated.
3Serum test at base line with urine pregnancy test by local standards for other timepoints
4Pre-dose (prior to PRK, as applicable)
5PG sample may be drawn at any timepoint if missed at designated timepoint
6Patient may decline any PK blood draw and remain in the study with the agreement of the PI and sponsor
7First and second study eye (SE) will be established based on results of the dominant eye test.  SE will preferably be the non -dominant eye in the first treatment period, 
subject to investigator treatment decision. 
8ePRO VAS pain scores, study and rescue medication dose diary, and related questions will be collected at pre -specified time points (pre -dose, 1 hour, 3 hours, 6 hours, 
9 hours, 12 hours and prior to every dose until day 5 post -operatively) as instructed by the ePRO and described in the SOM.   VAS pain scores will also be collected for up 
to 24 hours following the final dose in each period, as detailed in the ePRO. In addition, for both periods 1 and 2, the foll owing timepoints will include VAS pain scores a t 
pre-dose (as stated above) AND 30 minutes after dose:  hours 6 (+30 minutes), 18 (+30 minutes), 24 (+30 minutes), and 30 (+30 minutes). ePRO devices will be collected 
when all assessments are complete.
9As collected by the site staff at each post -surgery visit (Days 1-4 in each period)
10e used as screening values rather than repeating assessments.
Study eye for current period = SE, assessments on both eyes = OU
13If bandage contact lens is still in p lace at Visit 6 or 11 (Study Day 8 for either period) , corneal staining will not be performed.
ge contact 
lens needs to replaced prior to day 4 , attempt to retrieve and store all used lenses.  
16Optional per Sponsor
* Patients may be followed for wound closure, at PI discretion, on study Days 5 -7 or after Day 8, until wound is completely healed.  On those visits, w ound size estimation 
by slit l amp should be performed , preferably by the same examiner , along with anterior segment OCT ,if available, at Sponsor’s option .  Other assessments are at PI 
discretion.  These additional visits and assessments will be optional for both sites and patients.
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 52
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Table 8-1 Details for highly  repetitive assessments
Study Phase Visit DayTime 
(post -
dose)PK blood
collection
Screening Screen -29 to -2 -
Baseline 1-1
-14+0-
Treatment 132 1Prior to 
dosePrior to 
dose4
0.25h X
0.5h X
1h X
2h X
3 2 24hPrior to 
dose
4 3 48h
5 472hPrior to 
dose
72.25h X
72.5h X
73h X
74h X
638 -
Treatment 23731Prior to 
dosePrior to 
dose4
0.25h X
0.5h X
1h X
2h X
8 2 24hPrior to 
dose
9 3 48h
10 472hPrior to 
dose
72.25h X
72.5h X
73h X
74h X
11 8 -
End of Study or Early Exit 12 30 days post -last dose (study med) -
1Patient may decline any PK blood draw and remain in the study with the agreement of the PI and sponsor
2Participating sites only , testing is at the Sponsor’s option
3Treatment Period 2 may begin any time after Day 8 assessments completed (including on Day 8), and up to 6 
weeks post first surgery.  If Day 1 of Treatment Period 2 is less than 1 week from Day 8 of Treatment Period 1, 
pre-dose ocular and vital sign assess ments (e.g., Blink rate, Body temperature) do not need to be repeated.
4Prior to PRK
Corporate Confidential 
Information
Novartis Confidential Page 53
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
8.2 Informed consent procedures
Eligible subjects may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), IRB/IEC -approved informed consent.
Novartis will provide to investigators a proposed informed consent form that complies with 
the ICHE6 GCP guideline and regulatory  requirements and is considered appropriate for this 
study . The informed consent form will also include a section related to optional future 
research which will require a separate signature if the subject agrees to future research.  
Any changes to the proposed consent form suggested by  the investigator must be agreed to b y 
Novartis before submiss ion to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the subject 
informed consent and should be discussed with the subject during the study  as needed. 
Any new information regarding the safet y profile of the investigational drug that is identified 
between IB updates will be communicated as appropriate, for example, via an Investigator 
Notification or an Aggregate Safet y Finding. New information might require an update to the 
informed consent and then must be discussed with the subject.
Ensure subjects are informed of the contraception requirements outlined in the Section 4 .2
(Exclusion criteria) and in Section 5.1 (Contraception requirements).
A copy  of the approved version of all consent forms must be provided to the Novartis monitor 
after IRB/IEC approval.
8.3 Subject screening
Re-screening will be allowed in communication with the Sponsor, on a case-by-case basis. 
Re-screened subjects will keep their original screening numbers.
Information on what data should be collected for screening failures is outlined in the 
SiteOperations Manual.
8.4 Subject demographics/other baseline characteristics
Subject demographic and baseline characteristic data will be collected on all subjects.  
Relevant medical history/current medical conditions data will also be collected until signature 
of informed consent.  Details are outlined in the SOM.
Investigators have the discretion to record abnormal test findings on the medical history  CRF, 
if in their judgment, the test abnormality  occurred prior to the informed consent signature.
Corporate Confidential Information
Novartis Confidential Page 54
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
8.4.1 Drug screen
Drug test for drugs of abuse will be conducted at screenin g.  Testing to assess use of rescue 
medication will be conducted during treatment .  Samples will be sent to a central lab.  Results 
will be kept as source documentation.  Central lab details are included in central laboratory 
manual.
8.5 Efficacy  / Pharmacody namics
8.5.1 VAS (Visual A nalog Scale) pain assessment
VAS pain scores, study and rescue medication dose diary , and related questions will be 
entered in a provided device.  See SOM for details.
8.5.2 Oral analgesics use
Rescue medication use will be recorded in the eCRF and reconciled with patient entries in the 
provided electronic device.  See SOM for details.
8.5.3 Patient diary
VAS pain scores, study and rescue medication dose diary , and related questions will be 
entered in a provided device.  See SOM for details.
8.6 Safet y
Safet y assessments are specified below; methods for assessment and recording are specified in 
the SOM, with the Assessment schedule (Section 8.1 ) detailing when each assessment is to be 
performed.
8.6.1 Body tempe rature
See SOM for details.
8.6.2 Blood Pressure and Pulse Rate
See SOM for details.
The CRF should contain the blood pressure and pulse rate measurements. 
8.6.3 Blink Rate
Blink rate will be assessed as blinks per 1 minute, as per SOM andAssessment schedule . 
This data will be included in the clinical study  report.
8.6.4 Visual acuity
Best-corrected visual acuity  and uncorrected visual acuit y, together with the refractive 
correction (if checked) will be obtained in each eye separately . This assessment is to be 
performed prior to pupil dilation. The results will be recorded in the appropriate eCRF page.
Novartis Confidential Page 55
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
8.6.5 Slit lamp biomicroscopy
Slit lamp exam of the adnexae, conjunctiva/sclera, cornea, anterior chamber, iris, lens and 
undilated fundus exam will be obtained for each subject according to the Assessment schedule . 
Results from the slit lamp biomicroscopy  exam will be recorded in the appropriate eCRF page.
8.6.6 Intraocular Pressure (IOP)
See SOM for details.
8.6.7 Dilated fundus exam
Dilated fundus exam will be obtained for each subject according to the Assessment schedule .
8.6.8 Ocular hy peremia
Ocular hyperemia will be assessed by simple live scoring at the timepoints shown in the 
Assessment schedule . For more details refer to the SOM. This data will be included in the 
clinical study  report.
8.7 Pharmacokinetics
PK samples will be collected at the timepoints defined in the Assessment schedule , 
Section 8.1. Follow instructions outlined in the central laboratory  manual regarding sample 
collection, numbering, processing and shipment. See Section 8.9 regarding the potential use of 
residual samples.
In order to better define the PK profile, the timing of the PK sample collection may  be altered 
based on emergent data. The number of samples/bl ood draws and total blood volume 
collected will not exceed those stated in the protocol. 
SAF312 will be determined by a validated LC-MS/MS method; the anticipated Lower Limit 
of Quantification (LLQ) in plasma is 0.05 ng/mL . Concentrations will be expresse d as ng/mL .  
If feasible, bandage contact lenses (BCL) exposed to study  drug may be analy zed for residual 
drug exposure after treatment.  The bioanal ysis of SAF312 in BCL will be exploratory , and 
the LC/MS/MS method used for the purpose may not be validate d.  Concentrations below the 
LLQ will be reported as “zero” and missing data will be labeled as such in the Bioanal ytical 
Data Report.
For standard PK abbreviations and definitions see the list provided at the beginning of this protocol.
The following PK parameters may be determined as relevant using the actual recorded 
sampling times using non-compartmental method(s) with Phoenix ™ WinNonlin®
(Version 6.4 or higher): Cmax, Cmin (pre-dose), Tmax, AUClast, AUC0 -t, Clast and Tlast 
from the plasma concentration -time data. Other PK parameters maybe calculated if deemed 
necessary . The linear trapezoidal rule will be used for AUC calculation.
Novartis Confidential Page 56
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
8.8 Other assessments
8.8.1 Ocular assessments
8.8.1.1 Dominant ey e test
The dominant eye and the non-dominant eye of each subject will be identified with the 
dominant eye test. In each study  period, one eye (the subject of the PRK surgery ) will be 
selected as the study  eye (SE).  SE will preferably  be the non-dominant eye in the first 
treatment period, subject to investigator treatment decision. 
8.8.1.2 Wound size estimation by slit lamp exam
Adjust slit beam and angle of illumination to allow visualization of the corneal wound 
boundary .  Adjust beam height to approximate maximum horizontal (wound width) and 
vertical (wound height) of the surgical epit helial wound in millimeters . 
8.8.1.3 Tear Production
Tear production will be evaluated by Shirmer’s test, as per SOM and Assessment s chedule . 
This data will be included in the clinical study  report.
8.8.2 Corneal Staining
Corneal staining will be determined on a scale of 0-3 as the average from each of 5 zones 
(central plus 4 quadrants). Results will be recorded for each zone. This test will be performed 
using a slit lamp after instilling fluorescein into the lower palpe bral conjunctiva of both ey es.
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 57
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
9 Safety  mon itoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study  until the end of study  visit. Therefore, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the study  treatment are also 
considered an adverse event irrespective if a clinical event has occurred. See Section 9 .5 for 
an overview of the reporting requirements.
The occurrence of adverse even ts must be sought by non-directive questioning of the subject 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the subject during or between visits or through physical examination finding, laboratory  
test fin ding, or other assessments.
Instructions for reporting of adverse events commonly  associated with PRK surgery  have 
been added to the SOM.
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 58
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the followin g criteria:
they induce clinical signs or sy mptoms,
they are considered clinically  significant,
they require therapy .
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in patients with 
underl ying disease. Investigators have the responsibility  for managing the safet y of individual 
subject and identify ing adverse events.
Adverse events must be recorded on the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, and accompanied by  the following information:
1.the severit y grade 
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.its relatio nship to the study  treatment 
Yes or
No
3.its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.
4.whether it constitutes a SAE (see Section 9.2 for definition of SAE) and which seriousness 
criteria have been met  
5.Action tak en regarding investigational treatment.
All adverse events must be treated appropriatel y. Treatment may include one or more of 
the following: 
no action taken (e.g. further observation only )
investigational treatment dosage increased/reduced
investigationa l treatment interrupted/withdrawn
concomitant medication or non -drug therap y given
hospitalization/prolonged hospitalization (see Section 9.2 for definition of SAE)
6.its outcome (not recovered/not resolve d; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown). 
Information about common side effects alread y known about the investigational drug can be 
found in the IB.  Once an adverse event is detected, it must be followed until its resolution or 
until it is judged to be permanent, and assessment should be made at each visit (or more 
frequentl y, if necessary) of any changes in severit y, the suspected relationship to the 
investigational drug, the interventions required to treat it, and the outcome.
Novartis Confidential Page 59
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
The investigator must also instruct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes 
might reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis.
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition 
elective or pre -planned treatment for a pre -existing condition (that is unrelated to the 
indication under study ) and has not worsened since the start of study  drug
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definition s of a SAE given above and not resulting in hospital admission
social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at ri sk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (see Annex I V, ICH-E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospitalization but might jeopardize the 
subject or might require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or 
development of dependency  or abuse (see Annex IV, IC H-E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
Novartis Confidential Page 60
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual 
reporting to Novartis Drug Sa fety & Epidemiology (DS&E) as per Section 9.2.2 .
9.2.2 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 days following the last study  treatment must be 
reported to Novartis within 24 hours of learning of its occurrence as descr ibed below. 
Any SAEs experienced after this period should only  be reported to Novartis if the investigator 
suspects a causal relationship to study  treatment.
Note: SAEs reported by subjects deemed to be screen failures must be reported to Novartis as 
outlined here with appropriate information also captured in the CRFs as specified in the Site 
Operations Manual.
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at 
a different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separate ly as a new event.
Follow -up information provided must describe whether the event has resolved or continues, if 
and how it was treated, whether the blind was broken or not (if applicable) and whether the 
subject continued or withdrew from study  participat ion. Each re-occurrence, complication, or 
progression of the original event must be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence ) and is thought to be related to the study  treatment a Drug Safet y and 
Epidemiology  Department associate may urgently  require further information from the 
investigator for Health Authority  reporting. Novartis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study  
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory 
requirements in participating countries.
Follow the detailed instructions outlined in the SOM regarding the submission process for 
reporting SAEs to Novartis.   Note:  SAE s must be reported to Novartis within 24 hours of 
the investigator learning of its occurrence/receiving follow -up information.
9.3 Reporting Medication errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient/subject 
or consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the protocol.
Novartis Confidential Page 61
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  harmful ph ysical or psy chological effects.
All study  treatment errors and uses outside of what is foreseen in the protocol will be 
collected in the dose administration record (DAR) CRF.  Study  treatment errors are only  to be 
reported to Novartis Drug Safet y and Epidemiology  department if the treatment error is 
associated with an SAE.
All instances of misuse or abuse must be documented in the adverse event (AE) CRF 
irrespective of the misuse/abuse being associated with an AE/SAE. In addition, all instances 
of misuse or abuse must be reported to Novartis Drug Safet y and Epidemiology . As such, 
instances of misuse or abuse are also to be reported using the SAE form/CRF. Table 9-1
summarizes the reporting requirements.
Table 9-1 Summary  of reporting requirements for medication errors 
Treatment error typeDocument in Dose 
Administration (DA R) 
CRFDocument in A E 
CRFComplete SA E 
form/CRF
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes YesYes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see 
Section 9.1 and Section 9.2 , respectivel y.
9.4 Pregnancy  reporting
To ensure subject safet y, each pregnancy  occurring after signing the informed consent must 
be reported to Novartis within 24 hours of learning of its occurren ce. The pregnancy  should 
be followed up to determine outcome, including spontaneous or voluntary  termination, details 
of the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications.
Pregna ncy must be recorded on the Pharmacovigilance Pregnancy  Form and reported by the 
investigator to the local Novartis Drug Safet y and Epidemiology  Department. 
Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the pos sible relationship to the study  treatment.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
The study  drug must be discontinued, though the subject may stay in the study , if she wishes 
to do so. All assessments that are considered as a risk during pregnancy  must not be 
performed. The subject may  continue all other protocol assessments.
Novartis Confidential Page 62
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
9.5 Early phase safety  monitoring
The Investigator will monitor adverse events in an ongoing manner and inform the Sponso r of 
any clinically  relevant observations. Any required safet y reviews will be made jointly 
between medicall y qualified personnel representing the Sponsor and Investigator. 
Such evaluations may occur verball y, but the outcome and key discussion points willbe 
summarized in writing (e-mail) and made available to both Sponsor and all Investigator(s). 
Criteria pertaining to stopping the study /treatment or adapting the study  design are presented 
above.
When two or more clinical site(s) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by telephone if possible) of any 
new, clinically  relevant safet y information reported from another site during the conduct of 
the study  in a timel y manner.
10 Data revie w and database management
10.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and CRFs with the invest igators and their staff. 
During the study  Novartis employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrit y of the sites’ data. The monitor will visit the site to check 
the completeness of subject records, the accuracy  of entries on the CRFs, the adherence to the 
proto col and to Good Clinical Practice, the progress of enrollment, and ensure that study  drug 
is being stored, dispensed, and accounted for according to specifications. Key  study  personnel 
must be available to assist the monitor during these visits.
The invest igator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject's file. The investigator must also keep the original informed consent form signed by 
the subject (a signed copy  is given to the subject).
The investigat or must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the eligibility  criteria, documen tation of 
SAEs, and the recording of data that will be used for all primary  and safet y variables. 
Additional checks of the consistency  of the source data with the CRFs are performed 
according to the study -specific monitoring plan. No information in source documents about 
the identity  of the subjects will be disclosed.
Novartis Confidential Page 63
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
10.2 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms using fully validated software that conforms to 21 CFR Part 11 
requirements. Designated investigator site staff will not be given access to the EDC system 
until they  have been trained. Automatic validation programs check for data discrepancies and, 
by generating appropriate error messages, allow the data to be confirm ed or corrected before 
transfer of the data to the Sponsor. The Investigator must certify  that the data entered into the 
Electronic Case Report Forms are complete and accurate. After database lock, the investigator 
will receive copies of the subject data f or archiving at the investigational site.
Data not requiring a separate written record will be defined in the Site Operations Manual and 
Assessment schedule and can be recorded directly  on the CRFs. All other data captured for 
this study  will have an external originating source (either written or electronic) with the CRF 
not being considered as source.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
10.3 Database management and quality  control
Novartis staff or CRO staff working on behalf of Novartis review the data entered into the 
CRFs by investigational staff for completeness and accuracy  and instruct the site personnel to 
make any required corrections or additions. Queries are sent to the investigational site using 
an electronic data query . Designated investigator site staff is required to respond to the query 
and confirm or correct the data.
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activit ies (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronically  to 
Novartis.
Diary  and PRO data will be entered into an electronic diary  by the subject. The sy stem will be 
supplied by a vendor(s), who will also manage the database. The database will be sent 
electronically  to Novartis.
Randomization codes and data about all study  drug(s) dispensed to the subject and all dosage 
changes will be tracked using an Interactive Response Technology  (IRT). 
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. 
The code break functionality  will remain available until study  shut down or upon request of 
Novartis.
The occurrence of any protocol deviations will be determined. After these actions have been 
completed and the database has been declared to be complete and accurate, it will be locked 
and the treatment codes will be unmasked and made available for data analy sis. Any changes 
to the database after that time can only be made byjoint written agreement between the 
COAR Analy tics NIBR Franchise Head and the relevant NIBR TA Head.
Novartis Confidential Page 64
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
10.4 Data Monitoring Committee
Not required
10.5 Adjudication Committee
Not required
11 Data analy sis
Any data analy sis carried out independentl y by the investigator should be submitted to 
Novartis before publication or presentation.
11.1 Analysis sets
For all anal ysis sets, subjects will be anal yzed according to the stud y treatment(s) received.
The safety  anal ysis set will include all subjects that receive d any stud y drug.
The PK analy sis set will include all subjects with at least one available valid (i.e. not flagged 
for exclusion) PK concentration measurement, who received any study drug and with no 
protocol deviations that impact on PK data.
The primary PD analysis set will include all subjects who completed treatment through Day 4 
in both eyes/treatment periods with available PD data, and with no protocol deviations that 
impact PD data. The secondary  PD analysis set will include all subjects (completers and non-
completers) with available PD data, and with no protocol deviations that impact PD data.
11.2 Subject demographics and other baseline characteristics
All data for background and demographic variables will be listed by treatment sequence and 
subject. Summary  statistics will be provided for all subjects, as well as for each treatment 
sequence.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed by treatment seque nce and subject.
11.3 Treatments
Data for study  drug administration (rescue medication) and concomitant therapies will be 
listed by  treatment sequence and subject.
Corporate Confidential Information
Novartis Confidential Page 65
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
11.4 Analysis of the primary  variable(s)
The primary  aim of this study  is to evaluate the efficacy  of SAF312  eye drops on the 
pain in the immediate post- operative period.
11.4.1 Variable(s)
The primary  variables are visual analog scale (VAS) pre -dose pain assessment at 6 hours post -
operativel y, and the average ocular pain VAS assessments from the first post-operative 
assessment up to the pre -dose 12 hour post -operative assessment.
11.4.2 Statistical model, hypothesis, and method of analy sis
The primary  efficacy  analysis will assess the effect of SAF312  eye drops on the visual 
analog scale (VAS) pain assessment prior to the 6 hour dose post-operatively  compared to 
vehicle, and the average ocular pain VAS assessments from the first post-operative 
assessment up to the pre -dose 12 hour post -operative assessment compared to vehicle.
A longitudinal mixed effect model accounting for the cross -over effect with repeated 
measurement for VAS will be used.  The model will include fixed effects of treatment, hour 
post-operativel y, period, sequence, the treatment- by-hour post-operatively  interaction, the 
hour post-operativel y-by-period interaction, and the hour post-operatively -by-sequence 
interaction.  Repeated measurement over hour post- operativel y-by-period for each subject will 
be accounted for using the unstructured covariance matrix.  Kenward -Roger method will be 
used for approximating the denominator degrees of freedom.  Least square means will be 
estimated for each treatment -by-hour post-operatively  combination and the corresponding 
90% confidence intervals will be obtained.  The difference between SAF312 and vehicle, the 
p-value, and the corresponding 90% confidence interval will be obtained from the model at 
each time point.
A mixed effect model accounting for the cross -over effect for natural logarithmic transformed 
average (0-12hr) will be used.  The model will inclu de fixed effects of treatment, period, and 
sequence and a random effect of subject.  Kenward- Roger method will be used for 
approximating the denominator degrees of freedom.  Least square geometric means will be 
estimated for each treatment and the correspo nding 90% confidence intervals will be obtained.  
The difference between SAF312 and vehicle, the p-value, and the corresponding 90% 
confidence interval will be obtained from the model.
Efficacy  analyses will be performed on both of the primary  PD dataset (completers only) and 
the secondary  PD dataset (completers and non- completers). Completers are defined as patients 
who completed treatment through Day 4  in both eyes / treatment periods.   The primary 
efficacy  anal ysis will be the one based on the primary  PDdataset.
11.4.3 Handling of missing values/censoring/discontinuations
An additional equal number of subjects may be enrolled for subjects who withdraw from the 
study  for reasons other than safet y. Decisions regarding enrollment of these additional 
subjects will be discussed with the sponsor on a case- by-case basis.

Novartis Confidential Page 66
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
11.4.4 Sensitivity analy ses
To account for the potential influence of the rescue medication on the primary  endpoints, we 
plan to use three different approaches of analyzing the VAS pain scores and calculating the 
average (0-12hr) (assuming that the influence window of rescue medication is 4 hours): 
(1)any recorded VAS pain score at time points within 4 hours of the use of rescue medication 
will be considered missing; (2) all the recorded VAS pain scores will be used; (3) any 
recorded VAS pain score at time points within 4 hours of the use of rescue medication will be 
imputed by the record taken prior to the use of rescue medication. We will use the first 
approach as the primary  anal ysis, and the other two for help with the decision making.
11.5 Analysis of secondary  variable(s)
11.5.1 Efficacy  / Pharmacodynamics
The secondary  efficacy  analysis will assess the effect of SAF312 eye drops on whether 
patients need oral analgesics in12 hours, 24 hours, 2 days, and 3 days post-operativel y 
compared to vehicle, as well as the amount of oral analgesics needed in 12 hours, 24 hours, 2 
days, and 3 days post-operativel y compared to vehicle.  Number of patients who do not use 
oral analgesics from each treatment group will be repor tedby each assessment time post-
operativel y. McNemar’s test will be used to analyze the difference of the numbers of patients 
who take or do not take oral analgesics between SAF312 and vehicle.  The amount of oral 
analgesics needed will be analy zed at each assessment time post-operativel y.
Efficacy analy ses will be performed on both of the primary  PD completer -only dataset 
(completers only) and the secondary  PD all-subject dataset (completers and non-completers). 
Completers are defined as patients w ho completed treatment through Day 4 in both eyes / 
treatment periods.
11.5.2 Safety
The following safet y assessments will be descriptively  anal yzed:
AEs and SAEs
Vital signs (blood pressure, pulse rate, and bod y temperature)
Ocular assessments 
Visual acuit y
Intraocular pressure (IOP)
Dilated fundus exam
Ocular h yperemia
Size of epithelial defect by  slit lamp exam
Blink rate
Tear production
Epithelial defects

Novartis Confidential Page 67
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
Vital signs
All vital signs data will be listed by treatment group, subject, and visit/time, and if range s are 
available abnormalities (and relevant orthostatic changes) will be flagged. Summary  statistics 
will be provided by treatment and visit/time.
Adverse events
All information obtained on adverse events will be display ed by treatment group and subject.
The number and percentage of subjects with adverse events will be tabulated by body system 
and preferred term with a breakdown by treatment. An adverse event starting in one 
period/epoch and continuing into the next period/epoch is coun ted only in the onset period. 
Asubject with multiple adverse events within a body  system and treatment period/epoch is 
only counted once towards the total of this body  system and treatment.
Ocular assessments
All ocular assessments will be listed by treatment, subje ct, visit/ time and eye. 
Summary statistics will be provided descriptivel y by treatment, visit/time and ey e.
11.5.3 Pharmacokinetics
SAF312 plasma concentration data will be listed by treatment, subject, and visit/sampling 
time point. Descriptive summary  statistics will be provided by treatment and visit/sampling  
time point including the frequency  (n) of concentrations.
Summary  statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and 
geometric), median, minimum and maximum. An exception to this is Tmax where median, 
minimum and maximum will be presented. Concentrations below LLQ will be treated as zero 
in summary  statistics and for PK parameter calculations. A geometric mean will not be 
reported if the dataset includes zero values. PK parameters will becalculated as described in 
Section 8.5 and will be listed by  treatment and subject.
11.5.4 Pharmacokinetic / pharmacodynamic interactions
There are no known PD markers to be evaluated in the study . However, ocular surface 
temperature is being explored as a potential biomarker.
11.5.5 Other assessments
Not applicable
Corporate Confidential Information
Novartis Confidential Page 68
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
11.7 Sample size calculation
The study  will be considered positive if:
ocular pain VAS at 6 hours post -operativel y for SAF312 is statistically significantly lower 
compared to vehicle, OR
average of ocular pain VAS up to 12 hours post- surger y (average 0 -12 hrs) for SAF312 is 
statistically  significantl y lower compared to vehicle.
This study  will randomize approximately 40patients in a 1:1 ratio between two sequences, to 
provide approximate ly 30patients (60 eyes)evaluable for the primary  endpoints .  A total of 
60 eyes will provide approximately  83% power to reject the null hypothesis of equality  of 
mean VAS at the 0.1 level of significance (two -sided) in unilateral parallel design, assumin g a 
treatment difference of 20 mm and standard deviation of 30 mm. The basis for the treatment 
difference assumption is Sher e t al 1993 ,which is a study  comparing Diclofenac to vehicle on 
pain severit y in PRK subje cts wherein a treatment difference ranging from 15 mm to 30 mm 
Corporate Confidential Information
Novartis Confidential Page 69
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
(adjusted for a 100 mm scale) was reported between 6-hour and 12-hour post PRK with 
maximum difference observed at about 6 -hour post PRK time point.  With bilateral cross -over 
design, the power is expected to be higher than that estimated from the unilateral parallel 
design as we expect high correlation between the two eyes from the same subject.  
While there is no adequate data to inform exact sample size calculation for the average (0-12 
hrs) endpoint, we assume that the sample size based on the mean VAS will also be adequate 
for the comparison based on the average (0 -12 hrs) endpoint. 
11.8 Power for analy sis of key secondary  variables
Not applicable
Corporate Confidential Information
Novartis Confidential Page 70
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
12 Ethical considerations
12.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US Code of Federal 
Regulations Title 21, and Japanese Ministry  of Health, Labor, and Welfare), and with the 
ethical principles laid down in the Declaration of Helsinki.
12.2 Responsibilities of the invest igator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g. advertisements) and any other written information to be provided to subjects. 
Prior to study  start, the investigator is required to sign a protocol signature page confirming 
his/her agreement to conduct the study in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to Novartis monitors, auditors, Novartis Quality  Assurance representatives, designated 
agents of Novartis, IRBs/IECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform Novartis 
immediately  that this request has been made.
For multi -center trials, a Coordinat ing Investigator will be selected by Novartis around the 
time of Last Patient Last Visit to be a reviewer and signatory  for the clinical study  report. 
12.3 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report 
the results of this trial will be either submitted for publication and/or posted in a publicl y 
accessible database of clinical t rial results.
13 Protocol adherence
This protocol defines the study  objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of subjects should be 
administered as deemed necessary  ona case by case basis. Under no circumstances is an 
investigator allowed to collect additional data or conduct any additional procedures for any 
research related purpose involving an y investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved bythe IRB/IEC and health authorities, where required, it cannot be 
implemented.
Novartis Confidential Page 71
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
13.1 Protocol A mendments
Any change to the protocol can only be made in a written protocol amendment that must be 
approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
implementation.
Amendments that are intended to eliminate an apparent immediate hazard to subjects may be 
implemented immediately , provided the Health Authorities are subsequently  notified by 
protocol amendment and the reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, the report ing 
requirements identified in Section 9 (Safet y Monitoring) must be followed and the Study  Lead 
informed.
Novartis Confidential Page 72
Amended Protocol Version v02 (Clean) Protocol No. CSAF312X2201
14 References
Anttonen O, Junttila MJ, Rissanen H, et al (2007) Prevalence and prognostic significance o f 
short QT interval in a middle -aged Finnish population. Circulation p. 714 -20.
Bates BD, Mitchell K, Keller JM, et al (2010) Prolonged analgesic response of cornea to 
topical resiniferatoxin, a potent TRPV1 agonist. Pain p. 522 -8.
Mergler S, Valtink M, Co ulson -Thomas VJ, et al (2010) TRPV channels mediate 
temperature -sensing in human corneal endothelial cells. Exp. Ey e Res. p. 758 -70.
Murata Y, Masuko S (2006) Peripheral and central distribution of TRPV1, substance P and 
CGRP of rat corneal neurons. Brain Res. p. 87 -94.
Okada Y, Reinach PS, Shirai K, et al (2011) TRPV1 involvement in inflammatory  tissue 
fibrosis in mice. Am. J. Pathol. p. 2654 -64.
Pan Z, Wang Z, Yang H, et al (2011) TRPV1 activation is required for hy pertonicity -
stimulated inflammatory  cytokine release in human corneal epithelial cells. I nvest. 
Ophthalmol. Vis. Sci. p. 485 -93.
Qazi Y, Hurwitz S, Khan S, et al (2016) Validity  and Reliability  of a Novel Ocular Pain 
Assessment Survey  (OPAS) in Quantify ing and Monitoring Corneal and Ocular Surfa ce Pain. 
Ophthalmology  p. 1458 -68.
Sher NA, Frantz JM, Talley  A, et al (1993) Topical diclofenac in the treatment of ocular pain 
after excimer photorefractive keratectomy . Refract Corneal Surg p. 425 -36.
Sumioka T, Okada Y, Reinach PS, et al (2014) Impairm ent of corneal epithelial wound 
healing in a TRPV1 -deficient mouse. Invest. Ophthalmol. Vis. Sci. p. 3295 -302.
Woreta FA, Gupta A, Hochstetler B ,et al (2013) management of post -photorefractive 
keratectomy  pain. Survey  Ophthalmology  58(6):529 -35.
Yang Y, Y ang H, Wang Z, et al (2013 a) Functional TRPV1 expression in human corneal 
fibroblasts. Exp. Ey e Res. p. 121 -9.
Yang Y, Yang H, Wang Z, et al (2013 b) Wakay ama sy mposium: dependence of corneal 
epithelial homeostasis on transient receptor potential function. Ocul Surf p. 8 -11.
Zhang F, Yang H, Wang Z, et al (2007) Transient receptor potential vanilloid 1 activation 
induces inflammatory  cytokine release in corneal epithelium through MAPK signaling. J. Cell. 
Physiol. p. 730 -9.